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GLOSSARY 
 
Abuse: use of legal drugs inconsistent with / without medical prescription or use of 
illegal drugs 
 
Abuse liability: a potential to produce abuse 
 
Addiction: (= psychological dependence): a chronic and complex brain disease 
characterising by craving and high relapse rate 
 
Affinity: the "strength" of the interaction between a ligand and a receptor  
 
Agonist: a compound that binds to a receptor to form a complex which elicits a full 
pharmacological response, peculiar to the nature of the receptor involved  
 
Antagonist: a compound that bind to a receptor to form a complex which does not give 
rise to any response, as if the receptor were unoccupied 
 
Aversive motivation: a withdrawal behaviour produced by negative reinforcers or 
punishers  
 
Craving: a compulsion to drug seeking and taking; lose of control over drug use and 
continued use despite harm 
 
Dependence: (= physical or physiological dependence): a state of adaptation resulted 
from prolonged administration of a drug, manifested by withdrawal syndrome   
 
Ligand: a molecule which binds to a receptor to form a complex 
 
Neuralgia: a painful disorder of the cranial nerves 
 
Nociception: a pain sensation 
 
Opiate: opium derivatives, naturally occurring alkaloids and semi-synthetic derivatives 
of morphine, binding to any, or all, of the opioid receptor subtypes 
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Opioid: any compound possessing some affinity to any, or all, of the opioid receptor 
subtypes (endogenous opioids, opiates, fully synthetic opioids) 
 
Positive reinforcement: a stimulus (e.g., food) which presentation increases the 
probability or frequency of the behaviour it follows usually associated with a pleasant 
hedonic impact 
 
Pseudo-addiction: a drug-seeking behaviour (reminiscent of psychological addiction) 
exhibited by patients whose symptoms (e.g. pain) were under-treated. It tend to stop as 
soon as their pain is adequately treated 
 
Reinforcement efficacy: a strength of ability to act as a reinforcement 
 
Negative reinforcement: a stimulus (e.g. electric shock) which termination increases 
the probability or frequency of the behaviour its termination follows, usually associated 
with a unpleasant aversive impact 
 
Sensitisation: an increase in sensitivity to the recurrent stimulus 
 
Semi-synthetic opiate/opioid: a compound with some opioid receptor affinity, 
synthesised by functional modification of a product extracted from opium  
 
Synthetic opiate/opioid: a compound with some opioid receptor affinity, synthesised 
using no products extracted from opium, have structures unrelated to the opium 
alkaloids 
 
Tolerance: a decrease in effect of a drug following its repeated or prolonged 
administration  
 
Withdrawal syndrome: a drug class specific range of aversive symptoms (drug – 
opposite effects), occurring when the concerned substance is suddenly discontinued 
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INTRODUCTION 
 Opium, which is derived from the juice of the opium poppy (papaver 
somniferum), contains more than 25 distinct alkaloids. Two of them; morphine and 
codeine have an analgesic action. All compounds related to opium are opioids. 
Naturally occurring alkaloids and semisynthetic derivatives of morphine are opiates1.
 Opiates and antidepressants are frequently used for the treatment of various 
pain conditions. A combination of both drug classes may be more effective than either 
treatment individually and the opiate-treatment combined with an antidepressant may 
result in an opiate-sparing effect (see: page 22). Although it has been shown that 
antidepressants can attenuate self-administration (SA) of psychomotor stimulant and 
depressant drugs (see: page 23), it was not known whether they also attenuate SA of 
opiates.  
 Therefore the aim of this study was to investigate if antidepressants affect the 
abuse liability of heroin when tested in the intravenous SA (IVSA) paradigm and if 
antidepressants affect the rewarding properties of heroin when tested with the 
conditioned place preference (CPP) procedure. The effects of both, acute and 
subchronic administration of antidepressants with analgesic properties that do not 
reveal rewarding properties themselves, were investigated. 
1.1  OPIATES 
1.1.1 Acute and chronic effects of opiates: molecular level 
Opioid receptors 
 The properties of opioids derive from interactions with µ-(Fig. 1), δ- and κ- 
opioid receptors. Endogenous opioids binding to these receptors are enkephalins, 
endorphins and dynorphins. The activation of µ- and δ- opioid receptors results, among 
others in analgesia and reward. Activation of κ- opioid receptors results in analgesia 
and aversion. Rewarding properties of drugs may contribute to their abuse liability2 
(see: pages 14-16).  
 All opioid receptors have seven transmembranal domains and they are Giα/Gοα 
protein-coupled. The transmembranal and intracellular loop regions are similar for all 
opioid receptor types. Due to this similarity (~70%), most opioid ligands bind to more 
than one kind of opioid receptor with various affinity. External loops and terminal 
regions determine the receptor selectivity. The µ-receptor has a high affinity to 
enkephalins and beta-endorphins but a low affinity to dynorphins. The κ-receptor 
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shows a high affinity to dynorphins, δ- receptor to enkephalins. The binding of the 
agonist to the µ-receptor activates G protein-mediated pathways. 
 
Fig. 1. Common model of opioid receptor (modified from3). 
G protein-mediated pathways 
 The activation of opioid receptors leads to the activation of the extracellular 
signal related kinase (ERK) / mitogen activated protein kinase (MAPK) transduction 
cascade. Activated ERK and MAPK act on nuclear transcription factors, cytoplasmic 
enzymes, cytoskeletal proteins and ion channels4 ( 
Fig. 2). 
 Acutely administered opiates inhibit the adenylate cyclase (AC), the vesicular 
release, the Ca2+ conductance and the transmitter release but activate the K+ 
conductance (Fig. 3). The inhibition of the AC leads to a down-regulation of the cyclic 
adenosine monophosphate (cAMP) and to a decreased expression of the transcription 
factor cAMP response element binding protein (CREB)4.  
 Chronic administered opiates upregulate the cAMP pathway. This phenomenon 
is explained as compensatory homeostatic response to prolonged opiate inhibition. 
However, the molecular mechanisms underlying these adaptations are still unknown. 
The upregulation of the cAMP pathway increases the levels of various kinases e.g. 
protein kinase A (PKA), changes the expression level of several transcription factors5 
and the expression of certain genes6. Chronic opiates no longer activate K+ 
conductance but activate PKA and thereby increase the transmitter release (Fig. 3)4. 
 Thus, prolonged exposure to opiates results in an adaptive response of the 
nervous system. Changes in gene expression, mRNA translation, protein degradation 
and regulation of receptor sensitivity predict changes in structures of neurons and 
neuronal circuits. The adaptive mechanisms related to addiction on cellular, synaptic 
and network levels resemble the plasticity underlying learning and memory such as 
long term potentiation (LTP) and long term depression (LTD). These lead to changes in 
their functions e.g. tolerance, physical dependence (Tab. 1), alterations of learning and 
motivation expressed on physiological and behavioural level (see: pages 14-16). 
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Fig. 2. ERK/ MAPK transduction cascade.  
Three main pathways are activated by acute opioids use (left). β/γ- subunit can lead to; 
1) Recrutation of membrane proteins such as Ras-GRF. 2) Activation of 
phosphatidylinositol 3-kinase. 3) Stimulation of phospholipase C, release of Ca2+ from 
internal stores and production of diacyloglicerol that in turn activates protein kinase C. 
Targets for activated ERK/MAPK are nuclear transcription factors, cytoplasmic 
enzymes, cytoskeletal proteins and ion channels. Because morphine causes no or little 
internalisation of µ- opioid receptor, it is possible that the MAP pathway is under 
permanent opioid stimulation during a chronic drug treatment. After withdrawal, the 
adenylate cyclase superactivation can lead to an activation of the ERK/MAPK cascade 
through intracellular elevation of cAMP and activation of the protein kinase A. PIP2 
phosphatidylinositol 4,5-biphosphate; IP3; inositol 1,4,5-trisphosphate; PKC; protein 
kinase C. RAP1; RAS :small GTPases. (modified from4). 
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Effects of opiates on transmitter release  
 Acute administration of opiates inhibits transmitter release by several 
mechanisms. Chronic treatment with opiates leads to adaptations that result in 
changed regulation of transmitter release4 (Fig. 3). 
 
Fig. 3. Regulation of transmitter release from synaptic terminals after acute and chronic 
opioid treatment. Acutely administered opiates inhibit transmitter release by: the 
activation of K+ conductance, inhibition of Ca2+ conductance, or other mechanisms that 
has not been well characterised. Opiates inhibit also adenylyl cyclase (AC); however, it 
does not seam to play a role in the acute inhibition of transmitter release. After 
withdrawal from chronic administered opiates, the inhibition of transmitter release by 
opioids is changed. 1) Opioids no longer activate voltage-dependent K+ currents to 
inhibit release. 2) There is an upregulation of AC that increases transmitter release by 
activation of PKA. 3) The upregulated AC is sensitive to inhibition by opioids and 
represents a new, morphine-induced effector. 4) The increased AC activity increases 
the production of cAMP that is metabolized to adenosine such that adenosine tone and 
thus presynaptic inhibition mediated by A1 adenosine receptors is enhanced at some 
synapses (taken from4). 
1.1.2 Effects of opiates; physiological and behavioural levels 
 The strong opiate, morphine is a "gold standard" treatment with which other 
pain relievers are compared. Although morphine is accepted as an irreplaceable tool in 
pain management, it has several side effects7. Adverse effects produced by morphine 
include among others nausea, sedation, euphoria, respiratory depression, drowsiness, 
constipation, miosis and detachment from reality (Tab. 1). The listed adverse effects, 
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except constipation and miosis, disappear with chronic administration8. In addition, 
prolonged use of morphine can cause tolerance to its analgesic effect as well as 
psychological and physical dependence9. Morphine possesses a high (nanomolar) 
binding affinity for µ-receptors and at least a 10-fold lower affinity to δ- and κ-
receptors10. Experiments on µ-receptor knockout mice confirmed that the µ-receptor 
plays the most pronounced role in nociception, however it is also responsible for most 
of the unwanted effects of morphine11. As both, analgesia and dependence, are 
mediated through the same receptor, the attempts to separate therapeutic from 
unwanted effects had never succeed. Above described unwanted effects, to some 
degree, are similar for all opioid pain relievers. Therefore the treatment of side effects 
of opiates still is a part of pain management. Although morphine possesses strong 
rewarding properties, its euphoric effect is diminished in presence of pain. Moreover, 
the appropriate dosage and proper administration intervals allow to avoid 
dependence9. 
 
acute effect chronic effect withdrawal affected system 
euphoria tolerance dysphoria reward system 
analgesia tolerance pain pain modulation 
system 
constipation no tolerance diarrhoea digestive system 
drowsiness, sedation,  
slowed respiration,  
low blood pressure 
muscle relaxation, 
anxiolitic effect 
counter-
adaptation 
arousal, 
high blood pressure, 
jitters,  
muscle cramps,  
anxiety 
locus coeruleus and 
its connections 
Tab. 1. Some acute and chronic effects associated with use of opiates12 
Opiates in pain therapy 
 Since Serturner isolated morphine from opium in 1806, it was used for the 
therapy of pain, cough, diarrhoea, dysentery and a various other illnesses. Sir William 
Osler, renowned Canadian physician of the late 1800’s, remarked that morphine was 
“God’s own medicine”13. 200 years later, opioid drugs are still the most potent and 
effective pain relievers for the therapy of nearly all kind of pain, especially for treating 
postoperative pain and chronic cancer pain palliation14.  
 The binding of agonists to opioid receptors results in the inhibition of voltage-
dependent calcium ion channels, activation of potassium ion channels and inhibition of 
adenylate cyclase. Reduced calcium ion influx in presynaptic nociceptive afferents 
results in a decrease of neurotransmitter release. Enhanced potassium ion efflux in 
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postsynaptic neurons causes cell membrane hyperpolarisation and an increase in 
conductance15. Thus opiates produce analgesia by inhibition of excitatory signal 
transmission involved in pain mediation16.  
Pain modulatory pathway 
 Opioid receptors in the central nervous system, located at key points in pain 
pathways17 mediate supraspinal analgesia (Fig. 4). Opioid receptors located pre- and 
postsynaptically at interneurons of the substantia gelatinosa in the dorsal horn, 
inhibiting the pain signalling from primary afferents to secondary neurons of the 
ascending spinal pain pathway provide spinal analgesia18. One of the regions 
implicated in pain suppression is the periaqueductal grey (PAG) of the midbrain. It 
integrates descending information from the prefrontal cortex (PFC), the hypothalamus, 
the amygdala and the nucleus accumbens (NAcc)19 and ascending information from 
the dorsal horn of the spinal cord18. Opioids inhibit nociceptive transmission in the PAG 
and in several nuclei of the rostroventral medulla oblongata (RVM), including the 
nucleus raphe magnus and of the dorsolateral pons (DLP), including the locus 
coeruleus (LC)20;21, which in turn, can modulate the nociceptive transmission to the 
dorsal horns. The PAG sends ascending axons to the medial thalamus22 and 
orbitofrontal cortex, which also possess opioid receptors23. Opioid interneurons can 
inhibit the nociceptive afferents containing among others substance-P, glutamate and 
asparate24 and thereby inhibit the transmission of pain signalling. Acting in the limbic 
system, opioids can inhibit the emotional aspects of pain. Finally, acting on the 
ascending pathway, opioids can affect pain realisation.  
 
Fig. 4. Schematic of pain modulatory pathways. The descending inhibitory system 
(black) modulates the ascending pain signals (blue). Complex modulatory effects occur 
at each of these sites, as well as in the dorsal horn (modified from25). Limbic structures 
projecting to the periaqueductal grey (grey) can also modulate pain signalling19;26. DPL; 
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dorsolateral pons, LC; locus coeruleus. RVM; rostral ventral medulla n.raphe; raphe 
nuclei. 
Opioid addiction 
Addiction theories 
 Addiction is a complex disease of the central nervous system. It is characterised 
by intrinsic compulsion to drug seeking and taking as well as by high rate of relapse, 
even after a long period of abstinence27. It is widely believed that the feeling of a surge 
of euphoria is the primary reason why opioids are taken after first contact with it 
(acquisition phase). Other reasons for opioid taking may be anxiety relief and functional 
enhancement28. Repeated opioid use results in a tolerance to its reinforcing effect as 
well as in psychological and physical dependence29. Due to the “changed set point” 
model of drug addiction12, prolonged use of an addictive drug results in adaptative and 
counteradaptative neurobiological changes in the brain. These changes include:  
 
1) Desensitisation of ventral tegmental area (VTA) dopamine neurons projecting to 
the NAcc. As result the reward threshold is increased, “natural rewards” lose their 
rewarding (liking) value and the dose of the addictive drug must be increased to 
produce a primary rewarding effect30. 
 
2) Sensitisation of noradrenergic LC neurons. Addictive opioids inhibit the enzyme 
converting ATP to cAMP. As counteradaptation resulting from chronic opioid use, the 
amount of converting enzymes increases. Since the noradrenaline release is related to 
the cAMP level, it increases excessively and withdrawal syndromes occur during 
withdrawal from opioids31. 
 
3) Enhancement of sensitisation to environmental cues. The “addicted brain” 
remembers the environmental cues associated with the drug effect. During exposure to 
such cues the activity of cortical glutamate neurons increases rapidly. It drives activity 
of dopamine cells in VTA and noradrenergic cells in LC. The release of dopamine leads 
to “drug wanting” and craving, simultaneously the increased release of noradrenaline 
potentiates withdrawal syndromes32;33. 
 
 For a long time it has been thought, that the subject continues the drug taking 
habit to prevent the onset of withdrawal syndromes (the negative reinforcement 
theory)34. However, the degree of physical dependence does not predict the intensity of 
subsequent craving, nor does detoxification and recovery from physical dependence 
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prevent relapse to drug taking35. Moreover, several highly addictive drugs (e.g. 
cocaine) are not associated with the development of physical dependence36. Therefore, 
the attenuation of aversive withdrawal syndrome is not critical in the origin of addiction. 
It was also proposed that the subject continues the drug taking habit to obtain a reward 
(the positive reinforcement theory)37;38. However, not all substances possessing 
rewarding properties are abused39. Intrinsic or addiction-related deficiency in the 
mesolimbic dopaminergic transmission (elevated reward threshold) was suggested to 
be responsible for seeking for compensatory stimulation of this system and therefore to 
increase abuse liability (reward deficiency theory)40. At present, the factor widely 
believed to be responsible for relapse is craving. Craving is an intense incentive 
motivation (desire) to self-administer and re-experience the effect of the previously 
consumed drug37. It is present not only during continuous use of the drug, but also after 
long-lasting abstinence periods and may be developed on the basis of sensitisation of 
the mesolimbic dopaminergic system (incentive sensitisation theory)41. It was also 
proposed that the dopaminergic system is engaged in incentive learning of association 
between rewarded and conditioned stimuli. This process is affected by addictive drugs 
so that the association is stronger and craving occurs42. Finally, it has been observed 
that heroin addiction is more severe in subjects suffering from antisocial personality 
disorder related to the damage in the PFC43. Moreover heroine impairs the functioning 
of the PFC. Since this brain region is responsible for goal oriented behaviour and 
behaviour control, damage of this structure can predispose to impulsivity and lack of 
control over drug seeking and taking (cognitive deficit model)44;45.  
Motivation and reward 
 Rewarding properties of drugs and “natural rewards” arise from their interaction 
with the reward system of the brain. Activation of several brain areas causes 
pleasurable or aversive sensations. However, the medial forebrain bundle as its 
connection through the lateral hypothalamus to VTA mediates the most intense 
rewarding effects. Drugs, which excite dopaminergic neurons in the VTA and dopamine 
release in the forebrain, particularly in the NAcc, possess rewarding properties and 
probably abuse liability46. The VTA mediates information flow between the limbic 
system and the neocortex (Fig. 5). Acting on the limbic system, opioids influence, 
among others, mood, emotions and cognition47 and, by modulating projections to the 
PFC, change the goal-directed behaviour48. Due to their action on various brain areas 
(e.g. PFC, hippocampus amygdala), opioids may alter cognition, association process 
and perception47;49. The dopaminergic reward pathway is part of the motivational 
system. The motivational system is based on the extended amygdala, including the 
shell of the NAcc, the bed nucleus of the stria terminals (BNST) and the central nucleus 
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of the amygdala50. The extended amygdala has multiple connections with the limbic 
system and movement centres51. Therefore drugs, which activate the reward system 
may influence motivation (drug wanting). The stimuli recognized as rewarding 
(favourable for subject) act as positive reinforcers supporting an approach behaviour. 
The stimuli recognized as aversive (unfavourable and undesirable for the subject) act 
as negative reinforcers supporting an avoidance behaviour. Drugs acting as reinforcers 
in animal tests, often posses abuse liability52. Motivation depends on the organism’s 
intrinsic state and is regulated by homeostatic mechanisms. Therefore, reinforcing 
properties of natural rewards depend also on the organism’s intrinsic state and needs. 
Drugs such as morphine or heroin mimic the action of natural rewards. They produce 
not only a surge of pleasant feelings, but also lead to adaptive changes, which result in 
a disorder of the brain's inhibitory control mechanisms53. In healthy subjects, drug 
taking produces a saturation state and inhibits previous motivation. In addicted subject 
the homeostasis mechanism is disturbed and the motivation for drug seeking and 
taking is continuous53.  
Neurotransmitters affecting “reward system” 
 Endogenous opioid systems affect the dopamine release in the mesolimbic 
system where a "reward" tone seems to be mediated by β-endorphin in the VTA and an 
"aversive" tone, mediated by dynorphin in the NAcc54. Opiates activate the reward 
system by disinhibition of VTA neurons. The dopaminergic neurons in the VTA are 
usually under GABA inhibition. Opiates inhibiting VTA GABAergic interneurons55 
disinhibit VTA dopaminergic neurons and lead to an increase in the NAcc dopamine 
release56. Besides inhibitory GABAergic modulation, dopamine neurons in the VTA, 
also receive excitatory glutamatergic inputs from the medial PFC (mPFC), the 
pedunculopontine region and the subthalamic nucleus57. The glutamatergic input play a 
critical role in the regulation of the dopaminergic transmission in the VTA58;59. The NAcc 
also receives glutamatergic projections from the hippocampus, the amygdala, the 
septal nuclei and the PFC60. The activation of glutamate receptors in the VTA promotes 
a dopamine release in the NAcc and the PFC61;62. It has been suggested, that elevated 
levels of glutamate in the VTA would facilitate the opiate reward by activating 
dopaminergic neurons but an increase of glutamate in the NAcc would reduce the 
opiate reward by activating GABAergic cells63. It has also been reported that opioids 
acting presynaptically on µ-opioid receptors can inhibit glutamatergic projection to the 
VTA. Thus the final effect of opioids results from the relation between disinhibition and 
inhibition of dopaminergic neurons.  
 The role of serotonin and noradrenaline in opiate reward is not completely 
understood. Serotonin activates enkephalinergic neurons in the hypothalamus, which 
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inhibit GABAergic interneurons in the VTA and increase dopamine release in the NAcc. 
Moreover, the noradrenaline release in the mPFC attenuates morphine–induced 
dopamine release in the NAcc64. On the other hand, the serotonergic raphe nuclei65 
and the noradrenergic LC66 project to the VTA where an increase of extracellular 
serotonin and noradrenaline levels inhibits dopaminergic neurons and decreases the 
dopamine release in the NAcc (Fig. 5). A Chronic opioid treatment results in 
adaptations of the reward circuit. The presynaptic adaptation involves an increase in a 
GABA mediated inhibition and a glutamate mediated activation of dopaminergic 
neurons. The postsynaptic changes can involve increased activation of k-opioid 
receptors mediating dysphoria. 
hypothalamus
ventral tegmental
area (VTA)
nucleus
accumbens (NAcc)
substantia nigra
amygdala
hippocampus
rewardreward
serotonin
enkephalins
GABA
GABA
enkephalins
dopamine
dopamine
dopamine
dopamine
peduncupontine region
subthalamic nucleus
glutamate
glutamate
glutamate
noradrenalin
noradrenalin
serotonin
locus coeruleus
raphe nuclei
GABA
 
Fig. 5. Simplified diagram illustrating projections of the VTA. The main excitatory 
projections mediating reward (white) and the main inhibitory points in reward mediation 
(grey). 
Withdrawal 
 Some adaptations resulting from chronic opioid use (see: “addiction theories”) 
lead to the physical dependence resulting in withdrawal syndromes. Several aspects of 
physical dependence have been observed to be correlated with the increase of cAMP 
concentration in specific brain areas (Tab. 2)6. 
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area responsible for: 
LC physical dependence, withdrawal (?) 
VTA dysphoria during early withdrawal periods 
PAG dysphoria during early withdrawal periods, physical dependence, 
withdrawal  
NAcc dysphoria during early withdrawal periods 
amygdala conditioned aspects of addiction 
Tab. 2. The structure-dependent functional consequences of cAMP upregulation 
following repeated opiates administration6 
 
 Due to the selective blockade of several brain areas it was possible to 
determine further structures and projections involved in mediation of withdrawal 
syndromes (Fig. 6). 
 
 
Fig. 6. Brain areas and projections mediating opioid withdrawal. The central role in 
withdrawal plays the bed nucleus of the stria terminals (BNST) and the periaqueductal 
gray (PAG). The role of the locus coeruleus (LC) is speculative. Further areas involved: 
ventral noradrenergic bundle (VNAB), paraventricular hypothalamic nucleus (PVN), 
preoptic area (PO), noradrenergic cells (A1), nucleus tractus solitarius (NTS), nucleus 
accumbens (Nacc) , amygdala (Amyg), rostral ventromedial medulla (RVM), nucleus 
paragigantocellularis (PGi) (taken from4). 
1.1.3 Heroin  
 Although, the British chemist C.R. Alder Wright first synthesised heroin 
(=diacetylmorphine, diamorphine) in 187467, it did not appear on the market until 1898. 
The German company Bayer produced and sold a new drug named “heroin” as a non-
addictive morphine substitute and cough medicine for children. The brand name is 
derived from the German word heroisch and referred to as a “heroic treatment”. It soon 
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turned out that heroin is addictive68. In accordance to the Harrison Narcotic tax act, 
published in 1914, manufacturing, possessing or selling of heroin has been banned 
(www.historicaldocuments.com/HarrisonNarcoticsTaxAct.htm). In 1923 the U.S. 
congress claimed heroin to be illegal for medical use. The Rolleston Report in United 
Kingdom marked a compromise between medical professionalism and public policy 
in1926 with heroin becoming a legal prescription drug69. In the United Kingdom heroin 
was introduced for maintenance treatment of opiate addiction70 and is nowadays 
routinely used in the treatment of number of general medical conditions such as 
myocardial infarction, palliative care, pulmonary oedema and post-operative pain71. 
There is a considerable dispute in many other countries, whether heroin should be 
legalised for the treatment of pain, particularly for terminal cancer patients. Heroin is 
more potent and faster acting than morphine72. Heroin is a highly lipophilic derivative of 
morphine, synthesised by acetylation. The adding of acetyl groups facilitates the 
passage through cell membranes and thereby more compound reaches the site of 
action. When administered peripherally e.g. intravenously, it appears transiently in the 
blood with a half-life of about 3 min and crosses the blood-brain barrier in 15 - 30 s. 
The rapid penetration into the brain as well as the fast onset of action contributes to a 
high abuse potential of heroin73. The µ-receptor affinity of heroin is 10 - 100 fold lower 
than that of morphine. However, its metabolites (6-monoacetylmorphine and morphine) 
possess a high affinity to µ-receptors, which are responsible for its morphine-like 
effects74. Since the effects of morphine and heroin are mediated through the same 
mechanism, both drugs share common therapeutic effects and mostly, there is no 
marked difference in side effects75;76. However, studies investigating the high dose 
heroin versus morphine in intravenous drug users revealed that heroin produces fewer 
side effects than morphine77. 
1.2 ANITIDEPRESSANTS 
1.2.1  Antidepressants in therapy  
 Antidepressants are medications used to treat depressive disorders. The action 
of selective antidepressants is limited to one neurotransmitter, while broad-spectrum 
antidepressants may influence two or more neurotransmitters78. In spite of the fact that 
they belong to different pharmacological classes and have different action profiles, they 
all improve monoaminergic transmission which is disturbed in depression79. They seem 
to work by changing the amount of available transmitter amount, changing the 
sensitivity of receptors or by a combination of both mechanisms. The aim of most 
medications is the elevation in serotonin (to improve mood) and noradrenalin (to 
improve “drive”) level in the central nervous system80. Antidepressants are indicated to 
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treat various aspects of depression81, but can also be used to treat other conditions 
connected with emotion and mood disturbances. They are effective in obsessive 
compulsive disorder, premenstrual syndrome, post-traumatic stress disorder, anxiety 
and panic attacks, social phobia and eating disorders82. They are also applied in pain 
management83;84 (see below). For depression treatment antidepressants are typically 
delivered daily for at least 4 to 6 months. The effects of most antidepressants shows 
up 1-2 weeks after treatment beginning and takes up to 6 weeks to reach full 
effectiveness85. One possible explanation for the slow onset of action may lie in the 
necessity of neuroadaptation during the treatment of depression. It has been 
documented that stress and depression can lead to atrophy and cell loss in the 
hippocampus and the PFC, which belong to the limbic brain system involved in the 
pathophysiology of depression. This effect has been observed to be reversible by 
chronic but not by acute administration of antidepressants, which boosted 
neurogenesis in rats and humans hippocampus86;87. Thus, the time required for 
antidepressants to increase cell proliferation in rats’ hippocampus is consistent with 
treatment time required for its anti-depressant action. It was also postulated that the 
antidepressants which elevate the level of noradrenalin require desensitisation of the 
α2-adrenoceptors88, and the antidepressants, which elevate the level of serotonin 
require desensitization of the somatodendritic 5-HT1A autoreceptors for their 
antidepressive effect89.  
Antidepressants in pain therapy 
Noradrenaline, serotonin and pain 
 In the ventromedial nucleus of the hypothalamus the descending 
antinociceptive transmission is divided into two pathways. One pathway is serotonin- 
and another noradrenaline mediated. Both pathways descend through the PAG. The 
first one projects to the RVM including nucleus raphe magnus, the second one to the 
DLP, including LC20;21. Both, the serotoninergic nucleus raphe magnus and the 
noradrenergic LC project axons down to the dorsal horns, where they can inhibit 
responses to the nociceptive stimuli90. Because the noradrenaline and serotonin are 
involved in mediation of nociception, some antidepressants may be effective in 
management of pain. Since PAG receives input from structures implicated in the 
mediation of mood (NAcc) and emotions (amygdala)19 antidepressants can also 
modulate pain perception as they act on the limbic system. Antidepressants, especially 
these able to increase noradrenalin and serotonin level, have several uses in pain 
treatment, often as first-line therapy for many chronic pain syndromes, especially in 
treatment of neuropathic pain91. These act presynaptically on the nociceptive 
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transmission increasing the K+ conductance and therefore reduces the excitability of 
the neurons mediating noxious stimuli (inhibit the release of glutamate and substance 
P92). On the other hand noradrenalin and serotonin, which act postsynaptically, can 
increase the release of GABA and enkephalins92 (Fig. 7). Some antidepressants inhibit 
neuronal excitability acting as antagonists on NMDA receptors93 and on histamine 
receptors94. Adenosine receptors activated by antidepressants also exert multiple 
influences on the pain transmission95;96. The analgesic effect of antidepressants is 
reported to be stronger in agents with mixed-receptor or predominantly noradrenergic 
activity, rather than agents with serotonergic activity97. Although the role of tricyclics in 
pain management is better established than that of selective antidepressants, the new 
generation selective drugs show much better side-effect profile than tricyclics93. The 
tricyclic antidepressant desipramine as well as the novel antidepressant venlafaxine 
are effective in the treatment of neuropathic pain. Moreover, desipramine and 
venlafaxine support opioid therapy in patients who became tired and depressed due to 
suffering from pain for a long period of time. Desipramine produces analgesia by acting 
on the noradrenergic system98 and by affecting the spinal cord GABAB receptors99. 
The effect of venlafaxine seems to be mediated through the µ-, κ1- κ3- and δ-opioid 
receptor subtypes as well as the α2-adrenergic receptors100;101.  
 
 
Fig. 7. The effect of serotonin and noradrenaline on the nociception on the dorsal horn 
synapse.(modified from anatomy.ucsf.edu/ohara/noradrenaline_and_pain.htm).  
Excitatory (blue) and inhibitory (white) interneurons modulate pain signalling in primary 
nociceptive afferents. The nociceptive transmission can be inhibited by activation of 
presynaptic autoreceptors localised on nociceptive afferents and by activation of 
postsynaptic receptors localised on excitatory neurons innervating inhibitory 
interneurons. Noradrenaline acting on presynaptic α2- adrenergic receptors inhibits the 
release of glutamate and substance P92 and acting on α1 receptors102 activating 
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inhibitory (e.g. GABA) neurons. Serotonin acts via the 5HT1A receptors to activate 
inhibitory interneurons containing GABA and endogenous opioids103. However, it is 
possible that it acts also presynaptically to inhibit the excitatory nociceptive 
transmission92.  
Co-treatment: opiates + antidepressants 
 Prolonged use of opiates can result in tolerance to their analgesic action. To 
compensate the decrease in therapeutic effects, it is necessary to increase the dosage 
or to introduce complementary analgesics104. It is also necessary to administer 
medication to treat concurrent symptoms during all phases of pain management105-107. 
One group of drugs that can serve as effective adjunct to pain treatment with opiates 
are antidepressants108. Antidepressants, enhance the opiates induced analgesia in the 
treatment of cancer-related pain109;110 and postoperative pain111;112. Because these 
compounds do not share the abuse liability of opioids and are considered to have a 
less severe side-effect profile, they are generally considered as an attractive treatment 
alternative for pain25;113. 
1.2.2  Antidepressants and addiction 
Antidepressants abuse liability 
 Although antidepressants can elicit a withdrawal syndrome after treatment 
cessation, they generally do not cause craving, which is characteristic for drug 
addiction114. However, since dopamine has been postulated to play a role in 
depression115, the antidepressants that influence the dopamine system are likely to 
affect reward mediation116. Actually, a fast-acting and effective dopamine reuptake 
inhibitor nomifensine has been reported to be self-administered in rats and therefore to 
posses abuse potential117. Moreover, the noradrenaline and dopamine reuptake 
inhibitor bupropion, unlike other antidepressants, has been demonstrated to increase 
the brain reward function under baseline conditions in non-withdrawing subjects118. 
While selective serotonin reuptake inhibitors: paroxetine, fluoxetine und sertaline  
revealed some rewarding properties when testing in CPP paradigm, the selective 
serotonin noradrenaline reuptake inhibitor venlafaxine, tricyclic antidepressants 
amitryptiline119 and desipramine120 did not produce CPP nor CPA in rats. 
 For studying the effect of antidepressants on abuse liability of opiates, it was 
critical to choose antidepressants that are motivationally neutral and serve as 
adjuvants in the opioid therapy. Therefore for the present study desipramine and 
venlafaxine were selected. 
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Effect of antidepressants on abuse liability of other drugs 
 It was reported that antidepressants can attenuate SA of drugs with high abuse 
liability, such as psychomotor depressants and stimulants. For example, selective 
serotonin reuptake inhibitors, such as fluoxetine, catalpa, fluvoxamine or paroxetine 
were found to attenuate oral or i.v. SA of ethanol in rats and humans (e.g.,121-125) 
Fluoxetine was also reported to attenuate reinstatement of extinguished cocaine-
seeking behaviour126 and to decrease the rate of responding maintained by i.v. cocaine 
or amphetamine in rats127;128. While these studies suggest that antidepressants with a 
serotonergic mechanism of action can attenuate SA of abused drugs, it has also been 
reported that reboxetine, an antidepressant which selectively inhibits the reuptake of 
noradrenaline, attenuated SA of nicotine129. Therefore, it seems that antidepressants 
which block the reuptake of either serotonin or noradrenaline (or both) interfere with SA 
of psychomotor depressants and stimulants. Although it remains unclear whether these 
antidepressants can directly affect SA of opioid analgesics, it is interesting to note that 
fluoxetine improved the beneficial effect of the opioid receptor antagonist naltrexone on 
relapse prevention in heroin-dependent patients130. 
1.2.3 Venlafaxine  
 Venlafaxine is a new antidepressant that inhibits the reuptake of both serotonin 
and noradrenaline with different selectivity. Additionally it inhibits to a small degree the 
dopamine reuptake. It reveals a dose-dependent nonselectivity, which is unique among 
antidepressants. At low doses it acts primarily as an selective serotonin reuptake 
inhibitor, but at higher doses it also inhibits the reuptake of noradrenaline131;132. At the 
dose 10 mg/kg, venlafaxine inhibit both serotonin and noradrenaline reuptake133. 
Venlafaxine possesses a more rapid onset of clinical antidepressant action ( ≤ 7 
days)134 than tricyclic antidepressants. The half-life of venlafaxine is 5 h and that of its 
metabolite O-demethylvenlafaxine is about 11 h. Venlafaxine was reported to attenuate 
the reacquisition of morphine-induced CPP, as well as most morphine withdrawal signs 
in rats135, without producing rewarding or aversive effects by itself119. Therefore it was 
supposed that venlafaxine can affect morphine dependence.  
1.2.4 Desipramine 
 Desipramine is a tricyclic antidepressant. It has been reported to produce dose-
dependent and robust increases in cortical noradrenaline concentrations136. Although, 
desipramine is widely defined as a noradrenaline reuptake inhibitor, it inhibits also to a 
smaller degree the serotonin reuptake131. The onset of clinical antidepressant action of 
desipramine is slower (4 weeks), and its half life is 24h137. 
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2 Description of methods 
2.1 Choice of methods 
The mechanisms underlying the transition from occasional drug use to 
pathological abuse and addiction are not completely understood. Because the 
chemistry of the human and the rat brain is similar, the process of drug addiction may 
be the same for both138. Animal models can therefore be useful in the prediction of drug 
addictive properties. For instance, the Intracranial self-stimulation (ICSS) study enables 
the determination of brain areas mediating reward and the investigation of influences of 
various drugs on the brain reward threshold. The self-administration (SA) method 
allows the examination of reinforcing properties of drugs and the conditioned place 
preference (CPP) paradigm is used to determine the preference for cues associated 
with a drug effect. With the drug discrimination (DD) paradigm the effect of a test 
substance can be compared with the effect of a known addictive drug, as the animal 
can discriminate the “feel like drug” state139. Drugs possessing rewarding properties 
have often been observed to be self administered in animals and humans. Most of the 
drugs working as reinforcers in animal tests can cause addiction in humans. However, 
substances producing “feel like drug” state have not always an abuse liability.  
Because individual tests supply information about different aspects of various 
stages of the addiction cycle, it is reasonable to examine the abuse potential of drugs 
with complementary tests. From among several animal models that can be applied to 
investigate abuse liability of drugs, the IVSA and the CPP were chosen for this study. 
2.1.1 Self-administration  
It has been observed that laboratory animals voluntarily ingest psychoactive 
drugs140. The SA was reliably established with over 20 drugs that are abused in 
humans, but not with motivationally-neutral drugs. For this reason, the ability to support 
the SA behaviour (reinforcing property of a drug) can be considered as abuse liability of 
the drug. Because addiction is characterised by compulsive drug use even despite a 
harm, the compulsive pattern of SA in animals can imitate a drug abuse and predict a 
drugs addictive potential in humans. There are various possible routes of 
administration. Drugs can be delivered i.v.141, subcutaneously142, oraly143, intracranial144 
or by inhalation145. 
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Principles of intravenous heroin self-administration  
Because heroin is mostly administered i.v.146, an i.v. drug SA (IVSA) seems to be 
the most adequate animal model of the heroin use in humans. The IVSA training and 
test phases take place in an operant chamber (see: pages 26 and 44) where the 
animal implanted with intravenous catheter can move freely. The animal’s own 
behaviour (lever pressing) activates the infusion system resulting in delivery of heroin 
solution directly into the rats jugular vein (through chronic catheter connected to the 
infusion pump: see: pages 27-29 and 43). The number of heroin infusions depends on 
the frequency with which the animal presses the lever. Thus, the animal takes control 
over drug intake. Drug seeking and drug taking behaviour appears as result of a 
predictable temporal association between a subject’s own behaviour and a reinforcing 
effect produced by drug delivery140, based on the operant conditioning principle. There 
are various schedules of reinforcement that can be applied to examine drug SA. In the 
present study the fixed ratio and the progressive ratio schedules were used (see: 
pages 30-31 and 45-46). The SA paradigm allows to observe whether the drug of 
interest is self-administered (posses reinforcing properties itself), or to measure how 
the test drug affects the reliably established pattern of administration of a known 
addictive drug (affect reinforcing properties of addictive drug). SA allows the evaluation 
of the motivational effects of the test-drug during acquisition, maintenance (see: pages 
32-33 and 45-46) and relapse to drug-taking after the extinction period147. The main 
disadvantage of the IVSA method is a high animal attrition. The animals have to be 
implanted with an intravenous catheter. Because this procedure is highly invasive, a 
recovery period is required. The catheter could be easily blocked by thrombus, 
therefore it had to be daily flushed with saline containing heparin. The catheter is also a 
source of contamination and can be leaked or slipped out of the vein. Thus it increases 
the susceptibility to illnesses. If the catheter is permanently blocked or leaky, or if the 
vein is damaged the animal has to be excluded from the experiment148. Similarly, if the 
animal loses the connector pedestal fixed on the skull, it has to be excluded from the 
experiment 
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 Operant conditioning chambers 
6 operant chambers connected to the software, 
feeders and infusion pumps 
Inside of operant chamber  
  
Cover of soundproofed enclosure Infusion pump 
 
For description of operant chambers and infusion system see: page 43. 
Catheter implantation 
The SA method required chronic implantation of a catheter to infuse the heroin 
solution into the bloodstream just after completing the required correct response number. 
During the daily session the animal was allowed to receive up to 30 infusions. 
Assembling of the catheters 
The catheters (Fig. 8) were made from 3 different standard polyethylene (PE) tubings: 
 PE10 (1,5 cm); ( inside diameter (i.d.) 0.28 mm, outside diameter (o.d.) 0.61 mm. 
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 PE50 (12 cm); (i.d.) 0.58 mm, (o.d.) 0.965 mm. 
 PE160 (2cm); (i.d.) 1.14 mm, (o.d.) 1.57 mm 
The thin general purpose wire (33 gauge wire, 10cm lengths) was inserted into the P10 
tubing, so that the wire could be grasped on either end. Than the P10 was inserted 
(0.05 cm) into P50. The junction was heat sealed. The wire was removed. Similarly, the 
wire was inserted in PE160, the free end of P50 was inserted into the P160 and a heat 
seal was made. The catheter was flushed with distilled water to prove there was no 
leak149. 
 
 
Fig. 8. Intravenous catheter. 
Bounding technique 
Prior to the surgery all catheters were coated with penicillin/heparin by applying 
the following protocol. The catheters were soaked for 30 min in 5% 
tridodecylmethyloammonium chloride (TDMAC) in 95% ethanol. Next, they were dried 
and washed 5 times with sterile distilled water. Following, they were filled with penicillin 
solution (10mg/ml) and incubated for 30 min, they were air dried and washed 5 times 
with distilled water. Finally, they were filled with heparin solution (100 U/ml) incubated 
30 min, air dried and washed 5 times with distilled water. Due to this procedure the 
complexes TDMAC-penicillin and TDMAC heparin were built. Coating the catheter with 
antibiotic should prevent an infection and the coating with heparin should prevent a 
thrombus149. 
Surgery 
The surgical area was cleaned, covered with a sterile cloth and well lit. The 
heating pad was placed on the surgical table and a barrier sterile cloth was placed on 
it. Appropriate surgical instruments were sterilised and placed on another sterile cloth. 
The rat was weighed, anesthetised with a mixture of medetomidin (0.15 mg/kg), 
midazolam (2 mg/kg) and fentanyl (0.005 mg/kg), injected intramuscularly and it was 
checked for reflex. Making sure that narcosis acted, an ophthalmic ointment was 
placed in the animals eyes to prevent drying during surgery. The animal was shaved 
on the head, neck and on the chest and the shaved areas were cleaned with 70% 
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ethanol. To facilitate further procedures, the animal was immobilised in the stereotactic 
apparatus. The top portion of the skull was exposed with a scalpel and surgical 
scissors. 3 holes were drilled with a round dental drill and a connector pedestal was 
anchored to the skull with three surgical screws (using a round dental drill) and dental 
cement. After hardening of the cement, the animal was taken out of the stereotactic 
apparatus, transferred to a sterile surgical field and turned over on its back. The 
cannulation was performed due to ”Manual of Microsurgery on the Laboratory Rat”150. 
The external jugular vein was localised, a very small incision in the skin was made 
(with micro scissors) on the place were the pulse was seen. The vein was isolated 
(using forceps) and a very small cut was made on the top of it (using a pair of 
microvessel scissors). The catheter was connected to the syringe filled with saline, its 
free end (PE10) was inserted and secured to the vein with two sutures. The syringe 
was withdrawn in order to confirm that the catheter is in the vein (blood should come 
back into the catheter). The catheter was clumped off, disconnected from the syringe 
and its distal end was passed subcutaneously to the neck and than to an exposed top 
portion of the skull, where it was attached to a connector pedestal (PE160). The 
syringe was connected to the connector pedestal with a short piece of tubing and the 
catheter was flushed with saline to prove there was no leak. The skin was closed with 
the sutures. The pedestal tips were covered with a plastic cap when they were not in 
use. The wound areas were cleaned with saline and covered with aluminium powder 
(to prevent bleeding). The animal was injected with 0.5 ml of Baytril (1ml= 10mg 
enrofloxacin (antibiotic) + 30 mg butyl alcohol; to prevent infection). 
 After surgery, the rats were allowed to recover 5-7 days. Each day of recovery 
and after each experiment the catheters were flushed with 0.15 ml of a sterile saline 
solution containing heparin (1.25 U/ml) to prevent clotting and to maintain catheter 
patency. Moreover, before each daily operant session the catheters were flushed with 
0.15 ml sterile saline to prove whether the fluid flow was unaffected. When necessary, 
the catheter patency was verified by infusion of 0.1 ml 1% methohexical natrium (10 
mg/ml). Methohexical is an ultra-short-acting barbiturate and produces a rapid loss of 
muscle tone when administered i.v. Animals with non-patent catheters were excluded 
from the experiments. During the recovery animals were fed ad libitum. 
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Catheter implantation 
 
Fixation of the anesthetised rat in the 
stereotactic apparatus. Exposition of the top 
portion of the skull. Drilling the holes using a 
round dental drill. 
Fitting the stainless steel screws with forceps 
and screwdriver into the holes. 
Isolation of the external jugular vein. Insertion 
of the catheter. Fixation of the catheter to the 
vein with two sutures. 
Passing the distal end of the catheter 
subcutaneously to an exposed top portion of 
the skull. Attaching the catheter to connector 
pedestal anchored to the skull with 3 surgical 
screws and dental cement. Flushing the 
catheter. 
  
Closing the skin with the sutures. Covering the 
catheter tips with plastic cup. 
Final result. 
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General procedure 
 
Food restriction schedule 
 In order to facilitate the acquisition of operant behaviour, food was restricted to 
12 g/day for all rats during two to three weeks before starting the operant sessions151 
and in the course of the experiments (except the recovery period). Water was available 
ad libitum. The food was provided in the home cages at 3pm, if the animals were not 
trained or tested, or after each daily session in the course of experiments. 
 
Self-administration procedure 
 The rat was placed in an operant chamber. It was allowed to move free inside it. 
Due to the food deprivation, its exploratory behaviour was increased. Initially both 
levers were active (training and acquisition phases) and each lever press resulted in 
illumination of the stimulus light positioned above the activated lever, the activation of 
the food hopper and the delivery of a food pellet (food SA) or the activation of the 
infusion pump and the infusion of the heroin solution (IVSA of heroin). With the course 
of experiments only one lever remained active (maintenance phase), and only 
responses on this lever resulted in programmed consequences. There were two 
different schedules applied to reinforce correct responses. Box control (e.g. light 
illumination, activation of food hopper/infusion pump) and data acquisition (e.g. 
responses on both levers, reinforcements earned) were made using an interfaced 
computer software package (TSE-Systems, Bad Homburg, Germany). 
 
Fixed Ratio 
 The fixed ratio requires the animal to complete a fixed number of presses on the 
active lever to receive a reward. Under the fixed ratio schedule, the ratios remain stable 
during each daily session, however can vary with different sessions. The number of 
ratio refers to the number of correct responses which have to be completed to receive 
the food pellet or the heroin infusion (under the: fixed ratio:1– every response, fixed 
ratio:3 – every 3rd response, fixed ratio:5 – every 5th response and under fixed ratio:10 
– every 10th response was reinforced). The fixed ratio does not supply information 
about changes in reinforcement strength. 
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Progressive Ratio 
 The progressive ratio procedure is more complicated and slower learned by 
rodents then fixed ratio but it may be used as a direct measure of drug reinforcing 
efficacy149. Therefore it was reasonable to train the animals under the fixed ratio and to 
switch into the progressive ratio when the stable baseline was established.  
 After a stable and reliable response was established under the fixed ratio:10 
schedule, the rats were tested under the progressive ratio schedule of reinforcement. 
In the progressive ratio procedure the response requirements escalated following an 
exponential function during the experiment. Thus to receive each further infusion the 
subject had to increase its effort152. The ratios increased following each infusion during 
each daily session, according to the following exponential progression: 1, 2, 4, 6, 9, 12, 
15, 20, 25, 32, 40, 50, 62, 77, 95, 118, 145, 178, 219, 268, 328, 402, 492, 603, 737, 
901152. The consecutive numbers of this progression refer to the number of responses 
which have to be completed to receive each further infusion (Tab. 3). Thus to obtain 
the first infusion the rat has to press the appropriate lever 1 time, to obtain a second 
infusion the rat has to press the lever 2 further times (in total: 1+2 responses), to obtain 
the third infusion the rat has to press the lever 4 more times (in summary 1+2+4 
responses). To obtain the maximal allowed infusion number, the rat had to press the 
active lever 8445 times. 
 
ratio 
requirements 
1 2 4 6 9 … 32 … 268 … 901* … 901* 
response nr. 1 3 7 13 22 … 126 … 1378 … 4841 … 8445
infusion nr. 1 2 3 4 5 … 10 … 20 … 26 … 30 
Tab. 3.Relations between the ratio requirements, response numbers and infusion 
numbers under the progressive ratio schedule. 
* Since 26th infusion, the ratios increased always at 901.  
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Acquisition 
 It is widely believed, that the feeling of a surge of euphoria is the primary reason 
why heroin is taken after first contact with it. Thus during the acquisition (Fig. 9) of 
operant behaviour (lever pressing for heroin) the motivation to perform for heroin relies 
on its rewarding properties. 
 To investigate the effect of daily pre-treatment with venlafaxine on the 
acquisition of heroin SA, the rats implanted with a jugular catheter were randomly 
allocated into two groups. 30 min before each daily operant session Individuals without 
prior operant experience from the first group were injected with venlafaxine and from 
the second group with saline. The rats were placed in the operant chamber and 
allowed to lever-press for heroin. Acquisition phase consisted of four consecutive daily 
sessions, where the ratio requirements increased progressively during 4 consecutive 4 
h daily sessions due to the pattern illustrated below. The maximum possible infusion 
number was 30.  
 The food-reinforced experiment (control) was performed following similar 
procedure. However rats, not implanted with catheter, were trained to lever-press for 
food during 4 consecutive 45 min daily sessions. There was no maximum possible 
number of food pellets to obtain. 
 
FR1     FR3    FR5    FR10 FR10 PR
acquisition
response
stabilisation
maintenance
SA behaviour
 
Fig. 9. Acquisition phase of SA behaviour under the fixed ratio (FR) schedule. It 
consists of 4 experimental steps during which ratio requirements escalates. 
 33
Maintenance 
 During prolonged administration of heroin physical dependence and craving 
occurs. Thus, during the maintenance (Fig. 10) of operant behaviour, the motivation for 
lever pressing might result from rewarding properties of heroin, aversive withdrawal 
syndrome and incentive sensitisation to heroin. 
 To investigate the acute effect of antidepressants on the maintenance of heroin 
SA, the rats implanted with a jugular catheter were randomly allocated into the one of 
two groups. 30 min before each daily operant session, individuals that previously were 
trained to SA under increasing fixed ratio schedule and reached stable response level, 
from the first group were injected with venlafaxine and from the second group with 
saline. The rats were placed in the operant chamber and allowed to lever-press for 
heroin during 3,5 h. daily session. Maintenance of SA was tested under the fixed 
ratio:10 or under the progressive ratio schedule due to the pattern illustrated below. 
The maximum possible infusion number was 30. To investigate the chronic effect of 
antidepressants on the maintenance of heroin SA, prior to the described procedure, 
rats received once daily (Monday to Friday) a treatment with either antidepressant or 
vehicle (4 weeks before begin of the experiment).  
 The food-reinforced experiment (control) was performed under the fixed ratio:10 
schedule. Rats, not implanted with catheter, were trained to lever-press for food during 
15 min. daily session. There was no maximum possible number of food pellets to 
obtain. 
 
FR1     FR3    FR5    FR10 FR10 PR
acquisition
response
stabilisation
maintenance
SA behaviour
 
Fig. 10. Maintenance phase of SA behaviour. The maintenance phase follows the 
training phase of acquisition and the response stabilisation phase (until the animals 
reach stable reliable responding pattern). During maintenance the animals are tested 
under the fixed ratio:10 (FR10) and the progressive ratio (PR) schedule of 
reinforcement. 
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2.1.2 Conditioned place preference  
Principle of conditioned place preference  
 The CPP procedure in rats is used to determine the rewarding properties of the 
drugs and natural rewards153. It is easy implemented and not invasive. It allows testing 
high numbers of animals within a short time. However, moderate changes in rewarding 
properties of drugs may be difficult to detect with this method154. All experimental 
phases of CPP took place in the conditioning box consisting of three compartments 
(see: pages 35 and 69). During conditioning phase the animal is injected with a drug 
and than placed in one distinct compartment of the box, which is closed, so that there 
is no access to other compartments. The intrinsic motivational properties of the test 
drug (heroin injection) are paired with a previously neutral environmental cue set 
(compartment of experimental box) and, on the other day of conditioning, the properties 
of vehicle (saline injection) are paired with a different set of distinct environmental cues 
(another compartment of experimental box). When the treatment (unconditioned 
stimuli; UCS) becomes associated with the appropriate compartment, the 
environmental cue set acquires secondary motivational properties (conditioned stimuli; 
CS)154. Thus, development of this association bases on the principle of pavlovian 
(classical) conditioning. Because rewarding or punishing stimuli can evoke approach or 
avoidance respectively155, appropriate compartments can also provoke approach or 
avoidance. Therefore, when allowing the animal to choose among the training 
compartments on the test day, the animal will spend more time in the place associated 
with the rewarding drug effect. If a drug produces the CPP, this is one indication that its 
effects are rewarding and that it might therefore have abuse potential in humans. 
Because the treatment can affect behaviour, (e.g. locomotion) the expression of CPP is 
assessed in a test without drug154. The advantages of this method include its easy 
implementation, non-invasive properties and short training sessions. The main 
disadvantage is that CPP test may give a false positive or false negative score154. 
Drugs producing CPP do not have to be addictive and on the other hand, drugs that do 
not produce CPP may have addictive properties. For example alcohol has been shown 
to produce CPP but also conditioned place aversion (CPA)156 or no effect157. Opposite 
effects have also been demonstrated for nicotine158;159 and caffeine160;161. The outcome 
of CPP experiments can differ depending on injection time, dosage, route of 
administration, the number and time of conditioning sessions. Finally, when testing a 
drug combination, the attenuation of place preference can be due to the decrease in 
rewarding properties of a treatment but it can also result from affected learning of 
association between drug effect and environmental cues154;162. 
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Conditioning system 
 
The TSE conditioning system 
 
The conditioning box in the soundproofed enclosure. 
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General procedure 
 An unbiased procedure, as described in Tzschentke139, was used. This 
procedure requires that during pretest animals do not show an unconditioned 
preference for either end-compartment (the time spent in both end-compartments is 
similar).  
 The standard conditioning procedure (Tab. 4) consisted of pretest, conditioning 
and test phases. During 15 min pretest an animal was placed in central (start) 
compartment and had an access to the whole apparatus. The time (min) spend in each 
compartment and the distance (mm) covered in each compartment were recorded by a 
system of light beams and photocells. During the conditioning phase, the rats were 
injected with vehicle or drug and 5 min (heroin, saline) or 20 min (antidepressants) 
later placed for 40 min in vehicle- or drug- paired compartment, respectively. The drug- 
and vehicle-paired side were randomly assigned to each animal. For 50 % of the 
animals the “striped” and for another 50 % of animals the „grey” compartment was 
coupled with a drug. The rats had access to only one of two end-compartments, which 
were closed in this phase of experiment. The way (mm) made during the session was 
measured. Each second of 6 conditioning sessions the rats were injected with a 
vehicle and each second with a drug. Thus, during conditioning, one side became 
associated with the vehicle and another one with the drug. There was a two-day break 
in the experiment between conditioning days 4 and 5 (weekend). During the test day, 
undrugged animals were placed for 15 min in the box (the central compartment was 
the “start compartment”). Free movement in the whole apparatus was allowed, the 
time spent in each compartment and the distance (mm) covered were recorded. When 
the drug was rewarding, the animals spent more time in compartment paired with it.  
Considering the drugs that should attenuate abuse liability of heroin, it is 
important to confirm that these compounds have no aversive properties themselves. 
The drugs producing CPP posses rewarding properties and with high probability can be 
abused. Therefore, to confirm that heroin but not the applied antidepressants 
possessed rewarding properties themselves, the ability of each drug to produce CPP 
was measured. Furthermore, it was investigated, whether acute and/or subchronic 
pretreatment with venlafaxine and desipramine can affect the acquisition of heroin 
CPP and/or the expression of already established heroin CPP. Finally, the effect on 
locomotor activity was investigated to find out if any compound of the used substances 
produces unspecific effects. 
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 To asses the effect on the acquisition of CPP behaviour, the pretreatment was 
administered before the conditioning sessions. To asses the effect on expression of 
CPP, the pre-treatment was administered before the test session.  
 
day phase aim duration 
0 pre-test  
without drug 
to confirm the lack of an initial preference  15 min 
1,3,5 conditioning  
with drug 
to associate one site with drug 40 min 
2,4,6 conditioning  
with saline 
to associate another site with a saline 40 min 
7 test without  
drug  
to measure a new preference; clear reward  
properties of tested drug were assessed 
15 min 
8* test  
with drug 
to measure a new preference in a drug-sate; 
un-specific action of tested drug was assessed 
15 min 
Tab. 4. Standard conditioning procedure.  
 
*Because the learning of the association between drug effect and environmental 
cues can be state dependent (the response that has been acquired in drugged state 
can only be reproduced when the subject is in the same state163), the expression of 
CPP was also assessed in a test with drug. None of the studied drugs (heroin, 
venlafaxine, desipramine) produced state-dependent effects (data not shown). 
 
2.2 Choice of drugs 
2.2.1 Heroin  
The development of addiction in humans takes an extended period of time164. To 
shorten the acquisition phase of SA behaviour under experimental conditions heroin, 
as a very potent opioid, was selected for this study. Heroin is one of the strongest 
analgesic ever used for pain treatment71 and it possesses strong reinforcing properties. 
Its rewarding and/or reinforcing properties were confirmed with the aid of several 
behavioural methods e.g. IVSA165, CPP166, ICSS167. A small dosage of heroin evokes 
the same effect like a high dosage of morphine72. Therefore it can be administered in a 
small volume. This is important, since only limited solution volume may be infused 
during experimental session. Finally, the rats learn to self-administer heroin very 
quickly165 and therefore the training time can be spared. For IVSA experiments, heroin 
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at dose 0.05mg/kg was selected, as it was producing the most pronounced rewarding 
effects and maintaining the most consistent self-administration in rats168. The same 
dose produced the greatest response rate in own pilot experiments (data not shown). 
 
 
2.2.2 Antidepressants  
 Some antidepressants possess rewarding properties and the potency to 
produce physical dependence (see: page 22) For studying the effect of 
antidepressants on abuse liability of opiates, it was critical to choose the motivationally 
neutral antidepressants that serve as adjuvant in opioid therapy. Therefore for our 
study desipramine and venlafaxine were selected. Previous to the beginning of the 
study, it was shown (preliminary experiments) that none of both antidepressants was 
able to produce SA behaviour. Furthermore, when introduced instead of heroin, 
neither venlafaxine nor desipramine supported the heroin established SA 
(unpublished data). Thus it was confirmed that both antidepressants have no 
reinforcing properties. 
 
Venlafaxine  
 The serotonin/noradrenaline reuptake inhibitor venlafaxine was selected for this 
study for several reasons. First, the compound is a clinically effective antidepressant 
with analgesic properties (for review, see113). In rat experiments, the dose used in the 
present study (10 mg/kg i.p.) was shown to have moderate, but significant analgesic 
effects in chronic pain models (168; own unpublished results). In addition, venlafaxine 
was found to attenuate the reinstating effect of morphine in the CPP paradigm135. 
Subhan et al.119 showed that venlafaxine, at the dose and application conditions used 
in the present study (i.e., 10 mg/kg i.p., injected 30 min prior to testing), failed to 
produce either CPP or CPA. This suggests that the compound is “motivationally 
neutral”, and that a potential attenuation of heroin IVSA does not result from a simple 
additive effect of combining a rewarding and an aversive drug effect. Furthermore, it 
was reported that venlafaxine attenuates subjective effects of cocaine in humans169. 
Finally, since it remains unclear from previous studies whether serotonin or 
noradrenaline reuptake inhibition is more relevant for affecting drug intake, a 
compound, which combines both mechanisms of action was selected. 
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Desipramine  
 Desipramine was selected for this study as noradrenaline inhibitor because it is 
clinically effective in analgesia and sometimes co-administered with opioids (see: 
pages 22 and 55). Desipramine has no intrinsic reinforcing properties itself170. In a 
formalin test the dose used in the present study (10 mg/kg i.p.) significantly produced 
analgesia in rats171. However, the same dose of desipramine did not alter reward when 
tested in ICSS experiments172. This suggests that the compound is “motivationally 
neutral”, and that potential attenuation of heroin IVSA does not result from a simple 
additive effect of combining a rewarding and an aversive drug effect. Desipramine was 
found to reduce oral intake of amphetamine in a free choice experiment in rats173 and 
to facilitate both detoxification and abstinence maintenance in persons addicted to 
cocaine174;175. It was reported that desipramine may be a useful adjunctive medication 
in facilitating opioid and cocaine abstinence in opioid-maintained patients176. Moreover 
to some extent it reduces drinking in alcoholics who are depressed177. However, there 
is still a lack of data demonstrating effect of desipramine on opioid SA. 
 
3 The aim of the study 
 The aim of this study was to investigate if acute and subchronic administration 
of antidepressants with analgesic properties, that do not reveal rewarding properties 
themselves, may affect the abuse liability of heroin. The antidepressants of choice 
were venlafaxine, a selective serotonin/noradrenaline reuptake inhibitor and 
desipramine, an older generation tricyclic antidepressant with noradrenaline reuptake 
inhibitor properties.  
 The effect of antidepressants on the abuse liability of heroin was investigated 
with aid of two behavioural techniques; the IVSA and the CPP. The IVSA paradigm 
was involved to asses how administration of antidepressants will change the motivation 
to heroin taking in rats during acquisition and maintenance phase. The behavioural 
specificity of the pretreatment effect was assessed in a food–reinforcement paradigm 
(the 4th and 5th part of this study). Secondly, the CPP paradigm was used to assess 
how administration of venlafaxine and desipramine will change rewarding properties of 
heroin. Additionally, the control experiments measuring rewarding/aversive properties 
of each compound alone were performed. Furthermore the locomotor response during 
the conditioning was measured ( the 6th part of this study). 
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 4.1 Abstract 
 Opioids and antidepressants are frequently used for the treatment of various 
pain conditions. A combination of both drug classes may be more effective than either 
treatment alone, and combined treatment with an antidepressant may result in an 
opiate-sparing effect. Although it has been shown that antidepressants can attenuate 
self-administration of psychomotor stimulant and depressant drugs, it is not known 
whether they also attenuate self-administration of opiates. To determine whether 
venlafaxine, a serotonin/noradrenaline reuptake inhibitor with antidepressive and 
analgesic properties, affects acquisition and maintenance of intravenous heroin self-
administration in rats, male Long-Evans rats were trained to press a lever in order to 
receive heroin (0.05 mg/kg/infusion) under a fixed ratio or a progressive ratio schedule. 
A control group was trained in a fixed ratio food-reinforced operant procedure. The 
effect of venlafaxine on operant responding for heroin and food was assessed both 
during acquisition and, in separate groups of rats, during maintenance (i.e., after 
acquisition) of self-administration behaviour. Daily treatment with venlafaxine (10 mg/kg 
i.p.) before the operant session attenuated the acquisition of responding for heroin, but 
not for food. However, when tested during the maintenance phase in rats showing 
stable responding, acute treatment with venlafaxine only marginally affected operant 
responding for heroin under a fixed ratio:10 schedule of reinforcement, and neither 
acute nor subchronic (once daily during 4 weeks) venlafaxine treatment affected 
responding under a progressive ratio schedule. Thus, daily treatment with an 
antidepressant attenuates the acquisition of heroin self-administration in a 
behaviourally specific manner, while having only marginal effects on maintenance of 
heroin self-administration. 
 Keywords Addiction, Analgesics, Antidepressants, Drug abuse, Operant 
behaviour, Opioids, Reinforcement 
 
 Note: Results from this paper were in part presented at the EBPS workshop on 
Neurobehavioural Plasticity in Rome, Italy, 2-4 September 2004, and published in 
abstract form (Behav Pharmacol 15:A20). 
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4.2 Introduction 
 
 Because of their well-established analgesic properties, opioids are broadly used 
for the treatment of moderate to severe pain178. Unfortunately, opioid medication often 
coincides with development of tolerance to the analgesic effects, as well as with 
psychological and physical dependence. Moreover, their clinical use can be 
compromised by concomitant side-effects, like constipation, cognitive impairment and 
respiratory depression179. Preclinical and clinical studies have indicated that a number 
of antidepressants, including the tricyclic desipramine, and selective 
serotonin/noradrenaline reuptake inhibitors, such as venlafaxine and duloxetine, have 
intrinsic analgesic properties113;180. Because these compounds do not share the abuse 
liability of opioids and are considered to have a less severe side-effect profile, they are 
generally viewed as an attractive treatment alternative for particular chronic pain 
conditions, such as neuropathic pain25;113. In addition, it has been suggested that 
combination of antidepressants with opioids can improve analgesic efficacy and/or 
reduce dosing of opioids110;181. 
 Moreover, it was reported that antidepressants can attenuate self-administration 
of drugs with high abuse liability, such as psychomotor depressants and stimulants. For 
example, selective serotonin reuptake inhibitors, such as fluoxetine, citalopram, 
fluvoxamine or paroxetine were found to attenuate oral or intravenous self-
administration of ethanol in rats and humans (e.g.,121-125) Fluoxetine was also reported 
to attenuate reinstatement of extinguished cocaine-seeking behaviour182 and to 
decrease the rate of responding maintained by intravenous cocaine or amphetamine in 
rats127;128. While these studies suggest that antidepressants with a serotonergic 
mechanism of action can attenuate self-administration of abused drugs, it has also 
been reported that reboxetine, an antidepressant which selectively inhibits the reuptake 
of noradrenaline, attenuated self-administration of nicotine129. Therefore, it appears that 
antidepressants which block reuptake of either serotonin or noradrenaline (or both) 
interfere with self-administration of psychomotor depressants and stimulants. Although 
it remains unclear whether these antidepressants can directly affect self-administration 
of opioid analgesics, it is interesting to note that fluoxetine improved the beneficial 
effect of the opioid receptor antagonist naltrexone on relapse prevention in heroin-
dependent patients 183. 
 It was the aim of the present study to investigate whether the selective 
serotonin/noradrenalin reuptake inhibitor venlafaxine affects the acquisition and 
maintenance of intravenous self-administration of heroin in rats. Venlafaxine was 
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selected since this antidepressant was reported to attenuate the reacquisition of 
morphine-induced conditioned place preference, as well as most morphine withdrawal 
signs in rats135, without producing rewarding or aversive effects by itself119. 
Furthermore, since at the outset of the experiments it was not known whether 
serotonergic or noradrenergic reuptake inhibition would be more relevant, a drug was 
chosen that combined both mechanisms of action to maximize the chance to see 
effects in these initial experiments. The first experiment examined the effect of daily 
pretreatment with venlafaxine on acquisition of heroin self-administration under a fixed 
ratio schedule of reinforcement. Behavioural specificity of the pretreatment effect was 
assessed in a food–reinforcement paradigm. The second experiment investigated the 
effect of acute venlafaxine pretreatment on the maintenance of heroin self-
administration under a fixed ratio:10 schedule, and, again, specificity of the effect was 
assessed in a corresponding food–reinforcement paradigm. Finally, effects of both 
acute and subchronic (4 week) venlafaxine treatment on maintenance of heroin self-
administration under a progressive ratio schedule was investigated. 
 
4.3 Materials and methods 
4.3.1 Subjects 
 A total of 79 male Long Evans rats (Janvier Laboratories, Le Genest St. Isle, 
France), weighing 180–250 g at the start of the experiments, were used in these 
experiments. The animals were housed in groups of 5 in polycarbonate–cages before 
surgery, under the following standardized conditions: 12h light/dark cycle (0600–1800 
hours light), room temperature 20–24°C, relative humidity 35–70 %, 15 air changes per 
hour, and air movement <0.2 m/s. Initially, the animals had free access to standard 
laboratory chow (ssniff R/M-Haltung, ssniff GmbH, Soest, Germany). There were at 
least 5 days between delivery of the animals and the onset of the experiments. All 
experiments were conducted during the light phase and were in accordance with 
international guidelines for animal care (NIH publication No. 85-23, revised 1985) and 
approved by the local authorities (Bezirksregierung Köln, AZ 23.203.2). 
 
4.3.2 Apparatus 
 Six standard operant test chambers (TSE, Bad Homburg, Germany), housed in 
ventilated enclosures, were used. Each chamber was equipped with a stainless-steel 
grid floor and two levers. A house-light was positioned above the food-hopper, which 
was placed between the 2 levers. A yellow stimulus light was located above each lever. 
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An infusion pump (Razel Scientific Instrument, Stamford, USA) was connected to the 
catheter via polyethylene tubing (PE90). The animals were allowed free movement 
inside the chamber by means of a liquid swivel which was connected to a pedestal on 
the top of the skull of the animal via a tether. One lever was designated “drug active” 
and scheduled pressing on this lever resulted in activation of the infusion pump and 
presentation of the yellow stimulus light (for the duration of the infusion). Heroin was 
infused in a volume of 0.25 ml/10 s, 1 s per 100 g body weight. 
 When behaviour was reinforced by food, scheduled pressing on the active lever 
resulted in presentation of the yellow stimulus light and delivery of a 45 mg food pellet 
(Noyes precision pellets, Bilaney, Düsseldorf, Germany) to the food hopper. The white 
house light was on during the whole test session. Responses on the inactive lever had 
no programmed consequences. 
 
4.3.3 Surgery 
 Rats were implanted with a catheter in the right jugular vein under deep 
anaesthesia produced by a mixture of medetomidin (0.15 mg/kg), midazolam (2 mg/kg) 
and fentanyl (0.005 mg/kg), injected intramuscularly. The external jugular vein was 
isolated, and the catheter was inserted and secured to the vein with two sutures. The 
distal end of the catheter was passed subcutaneously to an exposed top portion of the 
skull, where it was attached to a connector pedestal anchored to the skull with three 
surgical screws and dental cement. Each day the catheters were flushed with 0.15 ml 
of a sterile saline solution containing heparin (1.25 U/ml) to prevent clotting and to 
maintain catheter patency. The pedestal tips were covered with a plastic cap when not 
in use. After surgery, the rats were allowed 5-7 days to recover.  
 When necessary, catheter patency was verified by infusion of 0.1 ml 1% 
methohexical natrium (10 mg/ml). Methohexical is an ultra-short-acting barbiturate and 
produces a rapid loss of muscle tone when administered intravenously. Animals with 
non-patent catheters were excluded from the experiments 
 
4.3.4 Procedure 
Food deprivation schedule 
 In order to facilitate acquisition of operant behaviour, food was restricted to 12 
g/day in all rats during two to three weeks before the start of the operant sessions151 in 
order to maintain rats at approx. 85% of their free-feeding weight. Water was available 
ad libitum. 
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Experiment 1.1. Daily pretreatment with venlafaxine during acquisition of heroin 
self-administration 
 Venlafaxine (10 mg/kg i.p.; n=10) or saline (n=15) was administered 30 min 
before each daily operant session. Individuals without prior operant experience were 
trained to lever-press for heroin (0.05 mg/kg/infusion) under a fixed ratio schedule of 
reinforcement, where the ratio requirements increased progressively during 4 
consecutive 4 h daily sessions (day 1: fixed ratio:1, day 2: fixed ratio:3, day 3: fixed 
ratio:5, day 4: fixed ratio:10). The maximum possible infusion number was 30. 
 
Experiment 1.2. Daily pretreatment with venlafaxine during acquisition of lever-
pressing for food 
 Venlafaxine (10 mg/kg i.p.; n=10) or saline (n=10) was administered 30 min 
before each daily operant session. Rats without prior operant experience were trained 
to lever-press for food during 4 consecutive 45 min daily sessions, where the fixed ratio 
requirements were increased progressively as in experiment 1.1. (consecutive ratio 
requirements: 1, 3, 5, and 10 for each consecutive session, respectively). 
 
Experiment 2.1. Acute pretreatment with venlafaxine during maintenance of 
heroin self-administration under a fixed ratio schedule 
 Rats from experiment 1.1 that had been pretreated with vehicle before the 4 
daily sessions of heroin self-administration and that showed reliable operant 
responding under a fixed ratio:10 schedule of reinforcement after continuation of 
training (≥12 infusions/session on 3 consecutive days) were randomly allocated to one 
of two groups. One group (n=6) was injected i.p. with 10 mg/kg venlafaxine, and the 
other group received saline (n=9). Thirty min later all subjects were allowed to lever-
press for heroin (0.05 mg/kg/infusion) under a fixed ratio:10 schedule during a 3.5 h 
test session. 
 
Experiment 2.2. Acute pretreatment with venlafaxine during maintenance of 
lever-pressing for food under a fixed ratio schedule 
 Rats without previous drug history were trained to perform under a fixed ratio:10 
schedule for food reward. At the start of the experiment, they were trained to lever-
press under a fixed ratio:1 schedule during daily 45 min sessions. After the rats 
reached criterion (at least 100 pellets per session), the response requirement was 
progressively increased to fixed ratio:10 (consecutive ratio requirements: 3, 5, 10), and 
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session length was reduced to 15 min. Once responding was reliable (≥100 
pellets/session on 3 consecutive days), animals were randomly allocated to one of two 
groups. One group (n=20) was injected i.p. with 10 mg/kg venlafaxine, and the other 
group received saline (n=21). Thirty min later all subjects were allowed to lever-press 
for food under a fixed ratio:10 schedule during a 15 min test session. 
 
Experiment 3.1. Acute pretreatment with venlafaxine during maintenance of 
heroin self-administration under a progressive ratio schedule 
 Rats were initially trained to lever press for food under a fixed ratio:1 schedule 
during daily 45 min sessions. After the rats reached criterion (≥100 pellets per session), 
the response requirement was progressively increased to fixed ratio:10, as described in 
the previous experiment. Rats that showed 3 days of reliable responding (≥100 
pellets/session) were implanted with a catheter. After 4 to 6 days of recovery, during 
which they were fed ad libitum, rats were retrained to self-administer heroin (0.05 
mg/kg/infusion) under a progressive ratio schedule. Under this paradigm, the ratio 
increased during each daily session, according to the following exponential 
progression: 1, 2, 4, 6, 9, 12, 15, 20, 25, 32, 40, 50, 62, 77, 95, 118, 145, 178, 219, 
268, 328, 402, 492, 603, 737, 901152. Sessions lasted 3.5 h or until 30 min passed 
without response. After 4 days of training under the progressive ratio schedule, rats 
were randomly allocated to one of two groups and were tested 30 min after 
pretreatment with venlafaxine (10 mg/kg i.p.; n=6) or vehicle (n=11) during a 3.5 h 
session (or until 30 min passed without response). 
 
Experiment 3.2. Subchronic pretreatment with venlafaxine during maintenance of 
heroin self-administration under a progressive ratio schedule 
 Rats (n=19) were trained to self-administer heroin (0.05 mg/kg/infusion) under a 
progressive ratio schedule of reinforcement, according to the same procedure as 
described for experiment 3.1. During the whole 4-week period (except on the day of 
surgery), rats received once daily (Monday to Friday) treatment with either venlafaxine 
(10 mg/kg i.p.; n=10) or vehicle (n=9). After 4 days of progressive ratio training rats 
received venlafaxine (10 mg/kg i.p.) or vehicle and, 30 min later, were allowed to lever-
press for heroin as described for the test session of experiment 3.1.  
 
 47
4.3.5 Data analysis 
 The mean number (+ 1 S.E.M.) of reinforcers (food pellets or heroin infusions) 
was calculated for data presentation. Data were subjected to a one-way analysis of 
variance (ANOVA) with post-hoc Dunnett tests where appropriate. The level of 
significance was set at P<0.05. Asterisks in the figures indicate statistically significant 
differences between vehicle and venlafaxine treatment. 
 
4.3.6 Drugs 
 Venlafaxin
anaesthetic mix
Finland), midaz
Germany) was d
ml/kg body weigh
 
4.4 Results 
 Experiment 1.1
self-administra
 Venlafaxin
all fixed ratio re
F(1,17)=13.7, P
F(1,11)=2222.1, 
to be dependen
pronounced at hi
 e (synthesized at Grünenthal GmbH, Aachen, Germany) and the 
ture which consisted of medetomidin (Dormitor®, Orion Pharma, 
olam (Dormicum®, Roche, Germany) and fentanyl (Synopharm, 
issolved in saline, and administered in an application volume of 1 
t. Heroin (Macfarlan Smith, Edinburg, UK) was dissolved in saline. 
. Daily pretreatment with venlafaxine during acquisition of heroin 
 tione produced a robust attenuation of heroin self-administration across 
quirements tested [fixed ratio:1: F(1,19)=10.8, P<0.01; fixed ratio:3: 
<0.01); fixed ratio:5: F(1,11)=6.7, P<0.05; fixed ratio:10: 
P<0.0001; Fig. 11A]. The observed decrease in heroin intake tended 
t on the ratio requirement, such that the attenuation was more 
gher ratio requirements [F(3,23)=2.84, P=0.07]. 
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Experiment 1.2. Daily pretreatment with venlafaxine during acquisition of lever-
pressing for food 
 Venlafaxine did not affect the acquisition of lever-pressing for food across all 
fixed ratio requirements tested (Fig. 11B). 
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Fig. 11. Effect of daily pretreatment with venlafaxine (10 mg/kg i.p.) on the acquisition 
of (A) self-administration of heroin (0.05 mg/kg/infusion) and (B) lever-pressing for food 
under a fixed ratio (FR) schedule with increasing ratio requirements for each 
consecutive daily session (FR1 to FR10). Data are expressed as mean + S.E.M. 
number of (a) infusions, and (b) food pellets obtained per session. * P<0.05 as 
compared to vehicle pretreatment. 
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Experiment 2.1. Acute pretreatment with venlafaxine during maintenance of 
heroin self-administration under a fixed ratio schedule 
 Acute pretreatment with venlafaxine produced a small, but statistically 
significant, attenuation of heroin self-administration under a fixed ratio:10 schedule of 
reinforcement [F(1,13)=4.8, P=0.0495; Fig. 12A]. 
 
Experiment 2.2. Acute pretreatment with venlafaxine during maintenance of 
lever-pressing for food under a fixed ratio schedule 
 Acute pretreatment with venlafaxine did not affect lever-pressing for food under 
a fixed ratio:10 schedule of reinforcement (Fig. 12B). 
 
 
Maintenance, acute pretreatment 
 
Fig. 12. Effect of acute pretreatment with venlafaxine (10 mg/kg i.p.) on the 
maintenance of (A) self-administration of heroin (0.05 mg/kg/infusion) and (B) lever-
pressing for food under a fixed ratio (FR10) schedule. Data are expressed as mean + 
S.E.M. number of (A) infusions, and (B) food pellets obtained per session. * P<0.05 as 
compared to vehicle pretreatment. 
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 Experiment 3.1. Acute pretreatment with venlafaxine during maintenance of 
heroin self-administration under a progressive ratio schedule 
 Acute pretreatment with venlafaxine did not affect responding for heroin under a 
progressive ratio schedule of reinforcement (Fig. 13). 
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Fig. 13. Effect of acute pretreatment with venlafaxine (10 mg/kg i.p.) on responding for 
heroin (0.05 mg/kg/infusion) under a progressive ratio (PR) schedule. Data are 
expressed as mean + S.E.M. number of infusions. 
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 Experiment 3.2. Subchronic pretreatment with venlafaxine during maintenance of 
heroin self-administration under a progressive ratio schedule 
 Subchronic pretreatment with venlafaxine did not affect responding for heroin 
under a progressive ratio schedule of reinforcement (Fig. 14). 
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Fig. 14. Effect of subchronic pretreatment with venlafaxine (10 mg/kg i.p., once daily for 
2 weeks prior to surgery and operant testing) on responding for heroin (0.05 
mg/kg/infusion) under a progressive ratio (PR) schedule. Data are expressed as mean 
+ S.E.M. number of infusions. 
 
4.5 Discussion 
 
 While being of broad clinical utility, opioid analgesics carry the risk of 
dependence development and abuse. Therefore, when considering co-administration 
of opioids with antidepressants for the treatment of chronic pain, information about the 
abuse liability of the drug combination may be clinically relevant. There are a number of 
animal studies suggesting that repeated administration of antidepressants can enhance 
the behavioural and neurochemical effects of psychostimulants and direct dopamine 
agonists184-188. Moreover, Subhan et al.189 have shown that fluoxetine enhances the 
rewarding effect of morphine as assessed in a conditioned place preference paradigm. 
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There are also anecdotal clinical reports of abuse of antidepressant drugs (e.g. 
fluoxetine190; amitriptyline191). On the other hand, various antidepressants were found 
to reduce the intake of psychostimulants and sedatives in animals and man (see 
Introduction). To our knowledge, the present study is the first that investigated the 
influence of an antidepressant on opioid self-administration. 
 The serotonin/noradrenaline reuptake inhibitor venlafaxine was selected for this 
study for several reasons. First, the compound is a clinically effective antidepressant 
with analgesic properties (for review, see113). In rat experiments, the dose used in the 
present study (10 mg/kg i.p.) was shown to have moderate, but significant analgesic 
effects in chronic pain models (e.g.168; own unpublished results). In addition, 
venlafaxine was found to attenuate the reinstating effect of morphine in a conditioned 
place preference paradigm135. Subhan et al.119 showed that venlafaxine, at the dose 
and application conditions used in the present study (i.e., 10 mg/kg i.p., injected 30 min 
prior to testing), failed to produce either conditioned place preference or aversion. This 
suggests that the compound is “motivationally neutral”, and that a potential attenuation 
of heroin self-administration does not result from a simple additive effect of combining a 
rewarding and an aversive drug effect. Furthermore, it was reported that venlafaxine 
attenuates subjective effects of cocaine in humans169. Finally, since it remains unclear 
from previous studies whether serotonin or noradrenaline reuptake inhibition is more 
relevant for affecting drug intake (see Introduction), we selected a compound which 
combines both mechanisms of action. 
 The present study showed that venlafaxine had an attenuating effect on the 
acquisition of heroin self-administration, as assessed in a fixed ratio paradigm. The 
effect of venlafaxine on heroin intake was considered to be behaviourally specific, as 
the compound did not affect acquisition of lever-pressing for food in a similar paradigm. 
However, once behaviour was well established under a fixed ratio:10 schedule, the 
same dose of venlafaxine only had a very small (albeit significant) effect on responding 
for heroin (while having no effect on responding for food). When using individual doses 
of a rewarding drug, decreases in drug intake could in principle be due to either an 
increase or a decrease in the rewarding effects of the drug. To circumvent this potential 
uncertainty, we also examined the effects of venlafaxine on heroin self-administration 
under a progressive ratio schedule of reinforcement. Here, acute treatment with 
venlafaxine had no influence on lever-pressing for heroin. In the progressive ratio 
experiment with acute pretreatment rats showed relatively low break point values; 
therefore, there might have been the potential risk of floor effects interfering with 
possible venlafaxine effects on heroin self-administration. However, in the subchronic 
pretreatment experiment, break point values were higher, and still no effect was seen. 
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Thus, interference by floor effects does not appear to be an issue for the acute 
experiment. Since clinical experience (e.g.192), as well as preclinical data (e.g.135), 
indicates that the effect of antidepressants can increase with repeated administration, it 
was tested in a further experiment whether subchronic pretreatment with venlafaxine 
would lead to a more pronounced effect on the maintenance of heroin self-
administration. Again, as assessed in the same progressive ratio paradigm, repeated 
administration of venlafaxine failed to affect responding for heroin. Taken together, 
these results suggest that venlafaxine attenuates acquisition, but not (or only 
marginally) maintenance, of heroin self-administration. 
 Although it remains unclear why venlafaxine differentially affected both phases 
of heroin self-administration, it can be hypothesized that it relates to differential effects 
of the compound on the underlying motivation to self-administer heroin during both 
experimental phases. It can be assumed that self-administration of heroin during 
acquisition mainly results from the positive reinforcing (most likely ´euphorigenic´, or 
rewarding) effects of the drug (for discussion, see193); on the other hand, it can be 
speculated that during maintenance, it might also have resulted (at least in part) from 
the negative reinforcing effects of heroin (i.e., suppression of withdrawal symptoms 
resulting from the development of physical dependence induced by repeated 
administration of heroin). According to this hypothesis, venlafaxine is able to attenuate 
the positive reinforcing effects of heroin, and therefore, attenuates acquisition of self-
administration. If, on the other hand, physical dependence contributed to the 
maintenance of heroin self-administration under the present experimental conditions, 
and venlafaxine has no effect on development or expression of physical dependence, 
this speculation could explain why venlafaxine had no (or only a minor) effect during 
the maintenance phase. 
 In operant paradigms, there is always the underlying concern that drug-induced 
changes in activity levels (in particular inhibition of activity) may affect the outcome of 
the experiments. In the present study we recorded responses on the inactive lever but 
have omitted that data because there were always very few responses on the inactive 
lever, thus making this measure unsuitable to detect a potential unspecific reduction in 
activity. In the above-mentioned unpublished CPP studies we found that venlafaxine 
(10 mg/kg i.p.), heroin (0.5 mg/kg i.p.) as well as the combination of both reduced 
locomotor activity only very slightly. 
Opioids produce their positive reinforcing or rewarding effect predominantly via 
disinhibition of dopaminergic neurons in the ventral tegmental area (VTA), resulting in 
increased extracellular levels of dopamine in the nucleus accumbens55. Both the 
serotonergic raphe nuclei and the noradrenergic locus coeruleus project to the 
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VTA65;66, and an increase of extracellular levels of serotonin and noradrenaline can 
inhibit dopaminergic neurons in the VTA via 5-HT1B/1C and/or 5-HT2B/2C receptors194;195, 
and adrenergic α1 receptors196, respectively. Thus, by elevating extracellular levels of 
serotonin and/or noradrenaline, venlafaxine may enhance the inhibitory influence of 
these transmitters on dopamine neurons and consequently counteract or attenuate the 
stimulatory effects of heroin on these neurons. If venlafaxine counteracts the heroin-
induced activation of dopamine release in the nucleus accumbens, this would reduce 
the rewarding effect of heroin, resulting in an attenuated acquisition of self-
administration. This assumption is indirectly supported by the finding that the selective 
serotonin reuptake inhibitor fluoxetine reduces brain stimulation reward197;198. We are 
currently testing the hypothesis that venlafaxine attenuates the rewarding effect of 
heroin, as assessed in a conditioned place preference procedure.  
As it may seem paradoxical that a compound which reverses deficits in the 
ability to experience pleasure (anhedonia) in depressed patients also is able to 
attenuate the rewarding effect of heroin, it is hypothesized that venlafaxine ´stabilizes´ 
the function of the brain reward system. According to this hypothesis, the direction of 
effect of venlafaxine would depend on the state of the reward system. When the 
function of this system is impaired, venlafaxine is hypothesized to enhance its reactivity 
to rewarding stimuli. On the other hand, when the system is (over)activated by external 
stimuli (e.g. heroin or electrical stimulation), the compound is expected to dampen the 
activity of the system. Obviously, since the responding for food was not affected, this 
latter assumption can only be applied to excessive and artificial (i.e. non-physiological) 
activation of the reward system. 
 In conclusion, venlafaxine was found to attenuate the acquisition of intravenous 
self-administration of heroin in a behaviourally specific manner; while having very little 
effect on responding for heroin in the maintenance phase. Thus, venlafaxine appears 
to moderately attenuate the abuse liability of heroin. On the other hand, it should be 
noted that the study did not find any indication for an enhanced intake of heroin. 
Therefore, it can be postulated that adding an antidepressant drug, such as 
venlafaxine, to an opioid for the treatment of pain would not be expected to enhance 
the abuse liability of the opioid (if anything, the combination might have a reduced 
abuse liability). It should be kept in mind that heroin is a strong opioid with very high 
abuse liability. If antidepressants like venlafaxine exert only a moderate modulating 
effect on the reinforcing/rewarding effect of opioids, the effects of heroin may be too 
potent to obtain clear and consistent effects of venlafaxine across different 
experimental conditions. 
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5 The tricyclic antidepressant desipramine non-specifically 
attenuates maintenance of intravenous self-administration 
of heroin under fixed ratio but not under progressive ratio 
schedule in rats 
 
Unpublished data 
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5.1 Abstract 
 Because co-treatment of opioids with antidepressants is widely applied in 
clinical praxis199, it is important to investigate the abuse liability of such a combination. 
In previous work venlafaxine revealed some effect on heroin IVSA. However, it was not 
clear whether this effect was due to the action on the serotonergic or the noradrenergic 
system or both. Therefore, in the present study it was investigated whether 
desipramine, a TCA that inhibits the reuptake of noradrenaline also affects heroin IVSA 
in rats. Male Long-Evans rats were trained to press a lever in order to receive heroin 
(0.05 mg/kg/infusion) under a fixed ratio and, in separate groups of rats, under a 
progressive ratio schedule. A control group was trained in a fixed ratio food-reinforced 
operant procedure. The effect of desipramine on operant responding for heroin and 
food was assessed during maintenance of SA behaviour. Acute treatment with 
desipramine (10 mg/kg i.p.) before the operant session attenuated the maintenance of 
responding for heroin under a fixed ratio. However, food-intake was also affected 
questioning the specificity of the effect. Furthermore neither acute nor subchronic (once 
daily during 4 weeks) pretreatment with desipramine (10 mg/kg i.p.) affected the 
maintenance of responding for heroin under a progressive ratio schedule. Thus, acute 
treatment with desipramine attenuated non-specifically the maintenance of heroin IVSA 
under a fixed ratio but not under a progressive ratio schedule. Therefore, we did not 
examine an acquisition of heroin IVSA. To determine if reduction in food intake resulted 
from inhibitory effect on locomotion, further studies involving CPP were performed and 
are described in the next part.  
 
5.2 Introduction 
 
 Antidepressants possessing intrinsic analgesic properties are supposed to be 
the most common adjuvant associated with opioid therapy199. Desipramine has been 
shown to provide analgesia for a variety of neuropathic syndroms200 and to reveal local 
anaesthetic efficacy in humans201. Because noradrenaline is involved in opioid 
analgesia but not side effects such as sedation or nausea, desipramine offers promise 
as opioid potentiator. According to clinical studies, chronic treatment with desipramine, 
increases and prolongs postoperative morphine analgesia202 and combination of 
desipramine and morphine produces more pronounced antinociception in postherpetic 
neuralgia than each drug alone203. The analgesic effect of antidepressants occurs 
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within 24 hours of administration and therefore appears to be independent on their 
antidepressant action which appears only after prolonged administration204.  
It is established, that desipramine, which has no intrinsic reinforcing properties 
itself170 helps to facilitate both detoxification and abstinence maintenance in persons 
addicted to cocaine174;175, and it is reported that desipramine may be a useful 
adjunctive medication in facilitating opioid and cocaine abstinence in opioid-maintained 
patients176. Moreover to some extent it reduces drinking in alcoholics who are 
depressed177. However, there is still a lack of data demonstrating the effect of 
desipramine on opioid SA. In a previous study it was found that venlafaxine, that 
inhibits both noradrenaline and serotonin reuptake, affected acquisition and, to a small 
degree, maintenance of heroin IVSA tested under a fixed ratio schedule. Therefore to 
determine if the obtained effect depends on serotonergic or noradrenergic action, in the 
present study the effect of desipramine was investigated. First, the effect of acute 
pretreatment with desipramine on maintenance of heroin IVSA under a fixed ratio:10 
schedule of reinforcement was examined. Behavioural specificity of the pretreatment 
effect was assessed in a food–reinforcement paradigm. Second, the effect of acute and 
subchronic (4 week) desipramine pretreatment on the maintenance of heroin IVSA 
under a progressive ratio schedule was investigated.  
 
5.3 Materials and methods 
5.3.1 Subjects 
 A total of 75 male Long Evans rats (Janvier Laboratories, Le Genest St. Isle, 
France), weighing 180–250 g at the start of the experiments, were used in these 
experiments. The animals were housed as described for venlafaxine (see: page 43).  
 
5.3.2 Apparatus 
 The Apparatus was the same as described for venlafaxine (see page: 43). 
 
5.3.3 Surgery 
 Rats were implanted with a catheter according to the procedure described on 
the pages 27-29 and 44. 
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5.3.4 Procedure 
Food deprivation schedule 
 Food deprivation schedule was the same as described for venlafaxine (page 
44).  
Experiment 1.1. Acute pretreatment with desipramine during maintenance of 
heroin self-administration under a fixed ratio schedule 
 The rats that received vehicle were treated and trained as described in 
experiment 2.1 with venlafaxine (page 45). On the test day, subjects (n=9) were 
injected i.p. with vehicle and 30 min later all subjects were allowed to lever-press for 
heroin (0.05 mg/kg/infusion) under a fixed ratio:10 schedule during a 3.5 h test session. 
Two days later subjects (n=4; because catheters of 5 subject became blocked) were 
injected i.p. with 10 mg/kg desipramine and 30 min later they were allowed to lever-
press for heroin (0.05 mg/kg/infusion) under a fixed ratio:10. The maximum possible 
infusion number was 30. 
Experiment 1.2. Acute pretreatment with desipramine during maintenance of 
lever-pressing for food under a fixed ratio schedule 
 Rats without previous drug experience were trained to self-administer heroin 
(0.05 mg/kg/infusion) due to the procedure described previously in experiment 2.1 with 
venlafaxine (page 45). Finally, one group (n=21) was injected i.p. with 10 mg/kg 
desipramine, and the other group received vehicle (n=21). Thirty min later all subjects 
were allowed to lever-press for food under a fixed ratio:10 schedule during a 15 min 
test session. 
Experiment 2.1. Acute pretreatment with desipramine during maintenance of 
heroin self-administration under a progressive ratio schedule 
 Rats were treated and trained to self-administer heroin (0.05 mg/kg/infusion) 
under a fixed ratio and progressive ratio schedules as described in experiment 3.1 with 
venlafaxine (page 46). After 4 days of training under the progressive ratio schedule, 
rats were randomly allocated to one of two groups and were tested 30 min after 
pretreatment with desipramine (10 mg/kg i.p.; n=4) or vehicle (n=4) during a 3.5 h 
session (or until 30 min passed without response). 
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Experiment 2.2. Subchronic pretreatment with desipramine during maintenance 
of heroin self-administration under a progressive ratio schedule 
 Rats (n=16) were treated and trained to self-administer heroin (0.05 
mg/kg/infusion) as described in experiment 3.2 with venlafaxine (page 46). During the 
whole 4-week period (except of the day of surgery), rats were treated once daily 
(Monday to Friday) either with desipramine (10 mg/kg i.p.; n=10) or vehicle (n=6). 
During the 4 days of PR training and on the test day (5th) rats received desipramine (10 
mg/kg i.p.) or vehicle and were allowed 30 min later to lever-press for heroin as 
described for the test session of the experiment.  
 
5.3.5 Data analysis 
 The mean number (+ 1 S.E.M) of reinforcers (food pellets or heroin infusions) 
was calculated for data presentation. Data were subjected to a one-way analysis of 
variance (ANOVA) with post-hoc Dunnett tests if appropriate. The level of significance 
was set at P<0.05. Asterisks in the figures indicate statistically significant differences 
between vehicle and desipramine treatment. 
 
5.3.6 Drugs 
 Desipramine (Sigma Aldrich, München, Germany) and the anaesthetic mixture 
which consisted of medetomidin (Dormitor®, Orion Pharma, Finland), midazolam 
(Dormicum®, Roche, Germany) and fentanyl (Synopharm, Germany) was dissolved in 
saline, and administered in an application volume of 1 ml/kg body weight. Heroin 
(Macfarlan Smith, Edinburg, UK) was dissolved in saline.  
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 5.4 Results 
 
Experiment 1.1. Acute pretreatment with desipramine during maintenance of 
heroin self-administration under fixed ratio schedule 
 Acute pretreatment with desipramine produced robust attenuation of heroin SA 
under a fixed ratio:10 schedule of reinforcement [F(1,12)=835.05, P<0.0001; Fig. 15A]. 
 
Experiment 1.2. Acute pretreatment with desipramine during maintenance of 
lever-pressing for food under a fixed ratio schedule 
 Acute pretreatment with desipramine produced robust attenuation of food SA 
under a fixed ratio:10 schedule of reinforcement [F(1.41)=66.8, P<0.0001;Fig. 15B]. 
 
 
Fig. 15. Effect of acute pretreatment with desipramine (10 mg/kg i.p.) on the 
maintenance of (A) heroin IVSA (0.05 mg/kg/infusion) and (B) lever-pressing for food 
under a fixed ratio:10 (FR10) schedule. Data are expressed as mean + S.E.M. number 
of (A) infusions, and (B) food pellets obtained per session. * P<0.05 as compared to 
vehicle pretreatment. 
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 Experiment 2.1. Acute pretreatment with desipramine during maintenance of 
heroin self-administration under a progressive ratio schedule 
 Acute pretreatment with desipramine did not affect responding for heroin under 
a progressive ratio schedule of reinforcement. However, this effect was on the 
borderline of significance [F(1.7)=5.8, P = 0.0523;Fig. 16]. 
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Fig. 16. Effect of acute pretreatment with desipramine (10 mg/kg i.p.) on responding for 
heroin (0.05 mg/kg/infusion) under a progressive ratio schedule. Data are expressed as 
mean + S.E.M. number of infusions. 
 
Experiment 2.2. Subchronic pretreatment with desipramine during maintenance 
of heroin self-administration under a progressive ratio schedule 
 Subchronic pretreatment with desipramine did not affect responding for heroin 
under a progressive ratio schedule of reinforcement (Fig. 17). 
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Fig. 17. Effect of subchronic pretreatment with desipramine (10 mg/kg i.p., once daily 
for 4 weeks prior to surgery and operant testing) on responding for heroin (0.05 
mg/kg/infusion) under a progressive ratio (PR) schedule. Data are expressed as mean 
+ S.E.M. number of infusions. 
 
5.5 Discussion 
 
 In a previous study it was shown that venlafaxine may reduce acquisition and, 
to a small extent, maintenance of heroin IVSA under a fixed ratio schedule. It was 
unclear if the observed effect was due to its serotonergic or noradrenergic action or 
both205. There are some evidences that noradrenaline is involved in mediation of opioid 
reward, tolerance and withdrawal syndromes (see below). Additionally, the dopamine 
and noradrenaline release in PFC has been linked to the emotional arousal evoked by 
stressful and rewarding environmental stimuli206 that trigger the relapse. Therefore it 
was investigated whether desipramine, a TCA, that inhibits the reuptake of 
noradrenaline, also affects heroin IVSA in rats.  
 Desipramine was selected for this study as noradrenaline inhibitor because it is 
clinically effective in analgesia and sometimes co-administered with opioids. In rats, the 
dose used in the present study (10 mg/kg i.p.) significantly produced analgesia in a 
formalin test171. However, the same dose of desipramine did not alter reward when 
tested in ICSS experiment172. This suggests that the compound is “motivationally 
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neutral”, and that potential attenuation of heroin IVSA does not result from a simple 
additive effect of combining a rewarding and an aversive drug effect. Moreover, 
desipramine revealed some efficacy in treatment of cocaine dependence174;175 and 
reduced oral intake of amphetamine in a free choice experiment in rats173. To my 
knowledge, there were no studies investigating the effect of desipramine on opioid SA. 
Psychostimulants and opioids act partially on the same neural substrates. For example, 
both increase dopamine levels in the shell of NAcc, VTA and in the amygdala207; the 
rewarding properties of both are controlled by α1b-adrenergic receptor in NAcc208 and 
for supporting their SA a ventral pallidum is critical209. Therefore, it was reasonable to 
examine if desipramine also affects heroin taking behaviour. Because the analgesic 
effect of antidepressants and their effect on morphine withdrawal135 may appear 
already with its single administration, the effect of acute administration of desipramine 
on heroin IVSA was tested. However, since chronic but not acute administration of 
antidepressant has been demonstrated to attenuate reacquisition of morphine induced 
CPP in rats135, it was also tested whether subchronic pretreatment with desipramine 
would lead to a more pronounced effect on the maintenance of heroin IVSA. 
 The present study showed, that acute administration of desipramine had an 
attenuating effect on the maintenance of heroin IVSA examined under a fixed ratio:10 
schedule. However this effect failed to be behaviourally specific, as the compound 
affected maintenance of food SA in a similar paradigm. 
 Desipramine was reported to decrease food intake in rats210 and in baboons211 
and to reduce binge–eating in patients with bulimia nervosa212. Thus, desipramine 
significantly affects the feeding behaviour itself. As “fight or flight” neurotransmitter in 
sympathetic nervous system, noradrenaline inhibits gastrointestinal activity213. Although 
antimuscarinic cholinergic effects of desipramine are not as pronounced as those of 
other TCAs214, it reduces saliva production and causes mouth dryness in man215 what 
also may contribute to a decrease in food intake. Moreover, due to its marginal action 
on histamine receptors desipramine possesses a weak potential to trigger sedative 
effects216.  
Changes in drug consumption may reflect changes in its reinforcing properties. 
However, decreases in a drug intake, when using individual doses of a drug testing 
under a fixed ratio schedule, could in principle be due to either an increase (earlier 
satiation) or a decrease in reinforcing effects of the drug. To find out, if the observed 
attenuation of heroin IVSA maintenance under a fixed ratio:10 schedule was due to an 
attenuation or an augmentation of reinforcing properties of a treatment, the progressive 
ratio procedure was applied. Due to receive each further infusion the subject had to 
increase the effort. Thus, the progressive ratio schedule was served as a direct 
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measure of drug reinforcing efficacy. Although desipramine (10 mg/kg i.p.) attenuated 
heroin IVSA maintenance under a fixed ratio:10 schedule, it did not affect responding 
for heroin tested under the progressive ratio schedule. The rats responding under a 
fixed ratio for heroin, obtained much higher average infusion number compared to 
progressive ratio conditions. Because the progressive ratio procedure is more stringent 
than a fixed ratio procedure, it may be supposed that the moderate effect observed 
under a fixed ratio was too weak to be revealed under the progressive ratio. 
Furthermore, while infusion number received under a simple fixed ratio schedule 
indicates the “rewarding” (liking) value of a treatment, the progressive ratio indicates 
“motivation” (wanting) to drug taking. 
 In the progressive ratio experiment with acute pretreatment rats showed 
relatively low break point values. Therefore, there might have been the potential risk of 
floor effects interfering with possible desipramine effects on heroin IVSA. However, in 
the subchronic pretreatment experiment, break point values were higher, and still no 
effect was seen. Thus, interference by floor effects does not appear to be an issue for 
the acute experiment. As acute but not chronic administration of desipramine 
decreases locomotor activity in rats, it can be supposed that tolerance develops to this 
suppressive effect217. The higher breaking point in subchronic pretreatment experiment 
may be related to this compensatory mechanism.  
As it may seem paradoxical that a compound which increases ability to 
experience pleasure in depressed patients also is able to attenuate the rewarding 
effect of heroin, it is hypothesized that desipramine ´stabilizes´ the function of the brain 
reward system. According to this hypothesis, the direction of effect of desipramine 
would depend on the state of the reward system218. If the function of this system is 
impaired, desipramine is hypothesised to enhance its reactivity to rewarding stimuli. On 
the other hand, if the system is (over)activated by external stimuli (e.g. heroin), the 
compound is expected to dampen the activity of the system. The partial confirmation of 
this hypothesis comes from studies investigating influence of desipramine on reward 
threshold in the ICSS paradigm. Desipramine decreased reward threshold in rats being 
in withdrawal from cocaine and therefore suffering from anhedonia (pathologically 
elevated reward threshold) but not in naïve rats219.  
In conclusion, desipramine attenuated the maintenance of heroin self-
administration under the fixed ratio:10 but not under the progressive ratio schedule. 
Because desipramine inhibited the intake of food under the fixed ratio:10 schedule the 
observed effect was not  specific. Thus behavioural inhibition contributed to attenuating 
effect of desipramine on heroin IVSA and the question, if desipramine affect abuse 
liability of heroin, remains open.  
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 6.1 Abstract 
 Venlafaxine, an antidepressant with serotonin- and noradrenaline reuptake 
inhibiting properties, has been reported to reduce acquisition (but not maintenance) of 
heroin intravenous self-administration (IVSA) in rats. The present study investigated 
whether this phase-dependent effect is due to an antidepressant-induced attenuation of 
the rewarding effect of heroin, as assessed in the conditioned place preference (CPP) 
paradigm. In order to study the effects of venlafaxine and the tricyclic antidepressant 
desipramine on acquisition and expression of heroin CPP, both compounds were 
administered prior to the conditioning sessions (together with heroin), or prior to the 
expression test after conditioning, respectively. As clinical evidence indicates that 
antidepressants require repeated administration for full efficacy, additional experiments 
were performed in which both antidepressants were administered for two weeks prior 
to conditioning, or for one week prior to the expression test, respectively. When tested 
alone, heroin (0.05 – 3.16 mg/kg i.p.) produced a dose-dependent CPP, whereas the 
antidepressants (1 – 21.5 mg/kg i.p.) produced neither a CPP nor a conditioned place 
aversion (CPA). For both antidepressants (10 mg/kg i.p.), neither acute nor repeated 
pretreatment affected acquisition or expression of heroin (0.5 mg/kg) CPP. Thus, the 
present study does not support the hypothesis that the previously observed attenuation 
of acquisition of heroin IVSA by venlafaxine is due to an antidepressant-induced 
attenuation of the rewarding effect of heroin. It is conceivable, however, that the 
rewarding effect of the 0.5 mg/kg dose of heroin was too pronounced to be susceptible 
to modulation by antidepressants. Alternatively, the modulation of acquisition of heroin 
IVSA in the previous study may be related to mechanisms that cannot be modelled with 
the CPP paradigm. 
 
 
Keywords: Abuse, Addiction, Antidepressant, Dependence, Opioid analgesic, 
Reinforcement, Reward 
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 6.2 Introduction 
 Opioids and antidepressants are drug classes which are frequently used for the 
treatment of pain. While opioids are still considered to be the golden standard for the 
treatment of severe acute pain178, antidepressants, in particular those that block the 
reuptake of noradrenaline, or both noradrenaline and serotonin, are becoming 
increasingly important for the treatment of various chronic pain conditions, such as 
neuropathic pain220. Moreover, a combination of an opioid and an antidepressant may 
be expected to offer additional benefits for the treatment of pain. First, the analgesic 
effect of each drug class may be additive, or even synergistic, resulting in a broader 
spectrum of analgesic efficacy113;221. Second, the addition of an antidepressant may 
produce an opioid-sparing effect, thereby leading to a reduction of opioid side-
effects181;222. Third, antidepressants may reduce the abuse potential of opioids by 
directly affecting their rewarding effect, or, indirectly, by improving depressed mood 
resulting from opioid withdrawal. Moreover, it is possible that antidepressants with a 
noradrenergic mechanism of action could attenuate physical dependency induced by 
opioids, as it is well established that clonidine, a noradrenergic α2-receptor agonist, 
reduces opioid-induced withdrawal symptoms223. Although clinical evidence that 
antidepressants affect drug abuse is still scarce, it has been demonstrated that they 
can reduce relapse in heroin or cocaine addicts224;225. Thus far, a comprehensive 
preclinical study of the interaction between antidepressants and opioids regarding the 
abuse potential of the drug combination has not been performed. 
 In a first series of studies, we investigated the effect of venlafaxine, an 
antidepressant with serotonin- and noradrenaline reuptake inhibiting properties, on 
heroin intravenous self-administration (IVSA) in rats205. In these experiments it was 
found that venlafaxine strongly attenuated the acquisition of heroin IVSA, while having 
little, if any, effect on maintenance of drug-taking behaviour. Interestingly, under the 
same experimental conditions, venlafaxine did not affect acquisition of food-reinforced 
operant behaviour, indicating that the attenuating effect of the antidepressant on 
heroin-reinforced operant behaviour was behaviourally specific (i.e., not merely a 
consequence of a non-specific suppression of behaviour). In that study, we also tested 
whether desipramine, a tricyclic antidepressant with noradrenaline reuptake inhibiting 
properties, was able to affect heroin IVSA. However, the combination of this compound 
with heroin resulted in a strong, non-specific suppression of operant responding, 
precluding unambiguous interpretation of the results (Magalas and Tzschentke; 
unpublished data). 
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The present series of experiments was performed in order to assess whether the 
previously observed reduction of heroin IVSA by venlafaxine was due to a direct 
attenuation of the rewarding effect of heroin. In order to avoid possible interference of 
disruptive effects on operant responding with the experimental outcome, we used the 
conditioned place preference (CPP) paradigm. After determining the CPP effects of 
heroin, as well as venlafaxine and desipramine alone, we studied the effects of acute 
and repeated treatment with both antidepressants on the acquisition and expression of 
heroin-induced CPP. 
 
6.3 Materials and Methods 
 
6.3.1 Subjects 
 Male Sprague-Dawley rats (Janvier Laboratories, Le Genest St. Isle, France), 
weighing 180–200 g at the start of the experiments, were used in these experiments. 
The animals were housed in groups of 6 in polycarbonate–cages under standardized 
conditions: 12h light/dark cycle (0600–1800 hours light), room temperature 20–24°C, 
relative humidity 35–70 %, 15 air changes per hour, and air movement <0.2 m/s. 
Animals had free access to standard laboratory chow (ssniff R/M-Haltung, ssniff 
GmbH, Soest, Germany) and tap water except during the conditioning and test 
sessions. There were at least 5 days between delivery of the animals and the onset of 
the experiments. All experiments were conducted during the light phase and were in 
accordance with international guidelines for animal care (NIH publication No. 85-23, 
revised 1985) and approved by the local authorities (Bezirksregierung Köln, AZ 
23.203.2). 
 
6.3.2 Apparatus 
 The conditioning boxes (TSE, Bad Homburg, Germany) had the following 
design: Each box consisted of 3 distinct compartments (2 end-compartments 
measuring 25x30x30 cm, and one compartment separating these end-compartments, 
measuring 10x30x25 cm). The separating walls between the central compartment and 
the end-compartments either did not (during conditioning sessions) or did (during test 
sessions) contain a door (9x10 cm) that allowed free movement of the animal between 
the separate compartments. The walls of one of the end-compartments was striped 
black and white (width of stripes 2 cm), and the walls of the other end-compartment 
was plain light grey (the shade of grey was such that both end-compartments had 
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approximately the same luminosity). The central compartment had plain white walls. 
The whole box was covered by a transparent plexiglas lid that held a light bulb in the 
centre above each compartment to provide dim illumination. The whole conditioning 
box was enclosed in a ventilated bigger wooden box that provided some degree of 
visual and acoustical isolation. The position and movements of the animal in the 
conditioning box were monitored by infrared light beams which were distributed along 
the sides of the box every 3 cm. 
 
6.3.3 Procedures 
 
General procedure 
 We used an unbiased procedure, as described in226. Pretests always confirmed 
that animals do not show an unconditioned preference for either end-compartment. 
Therefore drug- and vehicle-paired side were randomly assigned to each animal. The 
standard conditioning procedure involved a 15-min pretest (day 0), 6 conditioning days 
(alternating drug and saline treatment; 40 min sessions), and a 15-min test on day 7 
with undrugged animals. There was a two-day break in the experiment between 
conditioning days 4 and 5 (weekend). During conditioning, drugs were administered 5 
min before placing the animals in the box. In all experiments, the group size was n=8. 
 
Experiment 1 (place conditioning with heroin, venlafaxine and desipramine). In the first 
experiment, a range of heroin (0.05 – 3.16 mg/kg i.p.), venlafaxine and desipramine 
doses (1 – 21.5 mg/kg i.p., each) were tested using the standard procedure. 
 
Experiment 2 (effects of acute treatment with venlafaxine and desipramine on the 
acquisition of heroin CPP). In the second experiment, heroin (0.5 mg/kg i.p.) was 
coadministered with either saline, venlafaxine or desipramine during conditioning, 
following the standard procedure. Saline, venlafaxine or desipramine were injected 15 
min prior to heroin (i.e. 20 min prior to conditioning). 
 
Experiment 3 (effects of acute treatment with venlafaxine and desipramine on the 
expression of heroin CPP). In the third experiment, all rats were conditioned with heroin 
(0.5 mg/kg i.p.) following the standard procedure. However, on the test day (day 7), 
animals received either saline, venlafaxine or desipramine 20 min prior to the test 
session. 
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Experiment 4 (effects of subchronic treatment with venlafaxine and desipramine on 
the acquisition of heroin CPP). Prior to the conditioning experiment, different groups of 
rats received 2-week pretreatment (2x 5 days) with either saline, venlafaxine or 
desipramine (once daily). The respective treatment was continued during the 
conditioning phase, i.e. on ´drug days´ animals received heroin (0.5 mg/kg i.p.) plus 
their respective pretreatment, and on ´saline days´ animals received saline plus their 
respective pretreatment. That is, venlafaxine and desipramine were also administered 
during vehicle conditioning in order to avoid possible withdrawal effects after the 2-
week pretreatment phase. Saline, venlafaxine or desipramine were injected 15 min 
prior to heroin or saline (i.e. 20 min prior to conditioning). 
 
Experiment 5 (effects of subchronic treatment with venlafaxine and desipramine on 
the expression of heroin CPP). In the final experiment, all rats were conditioned with 
heroin (0.5 mg/kg i.p.) according to the standard procedure. After a drug-free test on 
day 7, animals were treated either with saline, venlafaxine or desipramine for 7 days. 
On the last of these days, a further test was conducted, 20 min after drug 
administration. 
 
6.3.4 Drugs 
 Heroin (Macfarlan Smith, Edinburg, UK), venlafaxine (synthesized at 
Grünenthal GmbH, Aachen, Germany) and desipramine (Sigma/RBI, Taufkirchen, 
Germany) were dissolved in saline and administered intraperitoneally (i.p.) at a volume 
of 1 ml/kg body-weight. 
 
6.3.5 Statistics 
  CPP data were analyzed with paired t-tests (two-tailed) comparing time spent in 
the drug- and vehicle-paired compartment on test day for each treatment group. 
Locomotor data were analyzed using two-factor ANOVA with repeated measures. The 
level of significance was set at P < 0.05. 
 71
 6.4 Results 
 
Experiment 1. Heroin produced a dose-dependent CPP (Fig. 18) (vehicle: t = -0.41, P 
> 0.05; 0.05 mg/kg: t = -0.91, P > 0.05; 0.1 mg/kg: t = 1.39, P > 0.05; 0.25 mg/kg: t = 
3.50, P < 0.05; 0.5 mg/kg: t = 4.82, P < 0.01; 1.0 mg/kg: t = 4.46, P < 0.01; 3.16 mg/kg: 
t = 3.72, P < 0.01). Heroin produced a biphasic effect on locomotor activity, with the 
lower doses producing locomotor stimulation and the highest dose producing locomotor 
reduction (Tab. 5). Neither venlafaxine nor desipramine produced a place conditioning 
effect at the doses tested (Fig. 19) (venlafaxine: 1.0 mg/kg: t = 0.07, P > 0.05; 4.64 
mg/kg: t = 0.38, P> 0.05; 10.0 mg/kg: t = 0.81, P< 0.05; 21.5 mg/kg: t = -0.34, P > 0.05; 
desipramine: 1.0 mg/kg: t = 1.20, P > 0.05; 10.0 mg/kg: t = -0.83, P > 0.05; 14.7 mg/kg: 
t = -0.21, P > 0.05; 21.5 mg/kg: t = -0.05, P > 0.05). While venlafaxine showed only a 
moderate reduction of locomotor activity at the highest dose tested (21.5 mg/kg), 
desipramine produced moderate to clear locomotor reduction starting at 10 mg/kg 
(Tab. 5). 
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Fig. 18: Experiment 1. Heroin was tested across a dose-range of approx. two orders of 
magnitude and produced a dose-dependent conditioned place preference (CPP). n=8 
rats per group. * P < 0.05 versus vehicle compartment 
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Tab. 5. Experiments 1 and 2 
acquisition experiments 
(conditioning days) 
 
1 3 5 
saline 46.9 ± 4.0 40.3 ± 2.5 48.2 ± 3.8 
1 48.1 ± 4.7 38.8 ± 1.7 42.2 ± 2.2 
4.64 46.1 ± 4,5 35.1 ± 2.7 42.1 ± 2.5 
10 39.8 ± 1.9 28.7 ± 1.2 38.6 ± 2.9 
venlafaxine 
21.5 33.6 ± 1.3 27.8 ± 0.7 32.7 ± 2.5 
1 46.7 ± 4.2 32.9 ± 3.7 34.1 ± 3.9 
10 31.8 ± 3.4 27.5 ± 1.6 33.0 ± 2.8 
14.7 34.9 ± 5.7 25.6 ± 2.8 30.4 ± 4.8 
desipramine 
21.5 27.2 ± 2.0 24.3 ± 2.4 28.1 ± 3.5 
0.05 72.2 ± 7,6 48.7 ± 7.3 52.0 ± 8.2 
0.1 95.1 ± 7.4 55.1 ± 7.4 66.7 ± 11.7 
0.25 75.1 ± 7.3 54.5 ± 5.1 64.0 ± 5.7 
0.5 48.5 ±  6.3 41.0 ± 4.3 44.4 ± 5.0 
1 51.4 ± 3.7 48.9 ± 6.1 56.5 ± 7.7 
heroin 
3.16 37.0 ± 9.1 29.0 ± 4.5 30.2 ± 4.2 
heroin + venlafaxine 0.5 + 
10 
44.1 ± 5.4 30.2 ± 3.7 46.0 ± 5.9 
heroin + desipramine 0.5 + 
10 
21.1 ± 3.4 17.7 ± 3.0 15.5 ± 1.6 
 
Locomotor activity during the conditioning sessions. Note that the data for refer to the 
activity of the animals in the drug-paired conditioning compartment during the 40 min 
conditioning sessions. Data are expressed as horizontal locomotion in m (± S.E.M.). 
n=8 rats per group. 
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Fig. 19. Experiment 1: Neither venlafaxine (A) nor desipramine (B) produced a place 
conditioning effect at any of the doses tested. n=8 rats per group. 
 
Experiment 2. Acute coadministration of saline, venlafaxine or desipramine during 
conditioning did not modify the acquisition of heroin-induced CPP (Fig. 20) (heroin + 
saline: t = 2.90, P < 0.05; heroin + venlafaxine: t = 3.23, P < 0.05; heroin + 
desipramine: t = 3.44, P <0.05). Venlafaxine did not alter the locomotor response to 
heroin, but desipramine combined with heroin produced a clear decrease in locomotor 
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activity (Tab. 5) (comparison vs. saline group: heroin + saline: F[1,14] = 0.001, P > 
0.05; heroin + venlafaxine: F[1,14] = 1.8, P > 0.05; heroin + desipramine: F[1,14] = 
157.7, P < 0.01). 
 
Experiment 3. Acute administration of saline, venlafaxine or desipramine prior to the 
test session did not modify the expression of heroin-induced CPP (Fig. 20) (heroin + 
saline: t = 2.45, P < 0.05; heroin + venlafaxine: t = 3.03, P < 0.05; heroin + 
desipramine: t = 2.95, P< 0.05). 
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Fig. 20. Experiments 2 and 3. The acquisition of CPP produced by heroin (0.5 mg/kg 
i.p.) was not affected by coadministration of venlafaxine (10 mg/kg i.p.) or desipramine 
(10 mg/kg i.p.) during conditioning. The expression of CPP produced by heroin (0.5 
mg/kg i.p.) was also not affected by administration of venlafaxine (10 mg/kg i.p.) or 
desipramine (10 mg/kg i.p.) just prior to the CPP test. In the acquisition experiment, 
animals did not receive any injection prior to the test; in the expression experiment, rats 
received an injection of the respective antidepressant only. n=8 rats per group. * P < 
0.05 vs. vehicle compartment. 
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 Experiment 4. Repeated (2-week) pretreatment with saline, venlafaxine or 
desipramine before conditioning, and continuing throughout conditioning, did not 
modify the acquisition of heroin-induced CPP (Fig. 21) (heroin + saline: t = 2.88, p < 
0.05; heroin + venlafaxine: t = 2.62, p < 0.05; heroin + desipramine: t = 3.21, p < 0.05). 
 
Experiment 5. Repeated (1-week) treatment with saline, venlafaxine or desipramine 
between conditioning and the test session did not modify the expression of heroin-
induced CPP (Fig. 21) (heroin + saline: t = 2.87, p < 0.05; heroin + venlafaxine: t = 
4.70, p < 0.01; heroin + desipramine: t = 2.67, p < 0.05). 
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Fig. 21. Experiments 4 and 5. The expression of CPP produced by heroin (0.5 mg/kg 
i.p.) was not affected when venlafaxine (10 mg/kg i.p.) or desipramine (10 mg/kg i.p.) 
were administered once daily for 1 week between conditioning and the CPP test. The 
acquisition of CPP produced by heroin (0.5 mg/kg i.p.) was likewise not affected when 
venlafaxine (10 mg/kg i.p.) or desipramine (10 mg/kg i.p.) were administered once daily 
for 2 weeks before and throughout the conditioning phase. N=8 rats per group. * p < 
0.05 vs. vehicle compartment. 
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 6.5 Discussion 
  In the present study we did not find any effect of venlafaxine and desipramine 
on heroin-induced CPP, regardless of the approach used (acquisition/expression, 
acute/repeated pretreatment). As far as the heroin-induced CPP reflects the rewarding 
effect of the compound, this suggests that the previously reported finding that 
venlafaxine reduced acquisition of heroin IVSA205 is not due to an attenuating effect of 
the antidepressant on the rewarding effect of heroin. However, before completely ruling 
out this hypothesis, particular procedural differences should be considered. In the 
present study, the 0.5 mg/kg dose of heroin was the lowest dose that reliably produced 
CPP (i.e., a clear supra-threshold dose) and was therefore selected for the interaction 
studies. In the IVSA experiments, the unit dose of heroin was 0.05 mg/kg/injection, and 
there were typically not more than 10 infusions during the 3h or 3.5h test session. Thus, 
animals received approximately equal amounts of heroin in both studies (although 
through different routes of administration), but in the present experiments that amount 
was injected as a bolus at one discrete time point. It may therefore be the case that the 
antidepressants were able to attenuate heroin self-administration because the 
“intensity” of the heroin stimulus was relatively low (small unit dose), while the effect of 
the bolus injection in the present study was too strong to be modulated. According to 
this hypothesis, one would expect that pretreatment with the antidepressants would 
only affect acquisition of IVSA of low (but not high) unit doses of heroin. 
  Place conditioning and self-administration are two models that are based on 
different behavioural principles. The principles underlying CPP are rather complex, but 
basically the model is based on mechanisms of classical conditioning, whereas IVSA is 
based on principles of operant conditioning. One major difference that may be relevant 
for the present context is that in place conditioning the drug is administered passively 
(non-contingently) by the experimenter, while in self-administration the drug is 
administered actively by the animal contingent upon its behaviour. There are many 
examples in the literature that non-contingently and contingently administered drugs 
can have different behavioural and physiological effects; it might thus be possible that 
the effects of heroin administered the one or the other way are differentially susceptible 
to modulation by antidepressant drugs. 
  The observed lack of effect of the antidepressants on heroin-induced CPP is 
consistent with the observation that the previously reported attenuation of heroin IVSA 
was not due to a disruption of learning processes (i.e., lack of effect on acquisition of 
lever-pressing for food). Only few preclinical and clinical studies have directly examined 
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cognitive effects of antidepressants, but most suggest that antidepressants do not 
overtly interfere with learning and memory processes and may even enhance cognitive 
performance227-230, although antidepressant-induced cognitive deficits have also been 
described231-233. The type of effect may be task-dependent and may also depend on the 
particular drug used and the duration of treatment. Overall, based on the literature we 
have no reason to assume that venlafaxine (and desipramine) exerted their effects on 
IVSA via an impairment of learning and memory processes. As mentioned above, if the 
antidepressants had impaired learning, they should also have disrupted the acquisition 
of heroin CPP. 
The same argument may in principle also be applied to the possibility that the 
antidepressants produced their effects on heroin IVSA via an attenuation or blockade of 
the discriminative stimulus properties of heroin. In order to evaluate this hypothesis, we 
are currently investigating whether venlafaxine affects the discriminative stimulus 
properties of opioids, as assessed in a drug discrimination procedure. 
 Although the CPP paradigm has been used previously to assess the 
motivational effects of antidepressants and their combination with drugs of abuse, 
these studies have produced equivocal results. With respect to antidepressants, 
Papp234 reported that imipramine, amitriptyline and citalopram produced CPA, whereas 
a CPP119;189;235 as well as no effect, was demonstrated for fluoxetine236. Subhan et al.119 
also showed CPA for amitriptyline, no effect for venlafaxine and sibutramine, and CPP 
for paroxetine and sertraline. In the present study, we found no effect for various doses 
of venlafaxine and desipramine. Because preference, aversion and neutral effects were 
found with compounds which inhibited either serotonin uptake, noradrenaline uptake, 
or both, it is unlikely that inhibition of either serotonin or noradrenaline reuptake 
consistently results in a particular motivational effect (i.e., either preference or 
aversion). 
 Regarding the interaction of antidepressants and drugs of abuse, previously 
reported findings are also heterogenous. On the one hand, fluoxetine potentiated the 
CPP-inducing effect of morphine189. On the other hand, fluoxetine did not modify 
ethanol-induced CPP236 and had no effect on opiate-withdrawal induced CPA237. 
Zarrindast et al.238 found that imipramine did not affect the acquisition, but blocked the 
expression of morphine-induced CPP, and venlafaxine, when administered for 1 week, 
but not when administered acutely, blocked morphine-induced reinstatement of 
morphine CPP135. In addition, Papp234 found that acute treatment during conditioning 
with imipramine, desipramine, amitriptyline, mianserin or citalopram diminished food-
induced CPP, while repeated (16 day) pretreatment prior to conditioning had the 
reverse effect and enhanced food-induced CPP. In addition, it may be noted that 
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fluoxetine was reported to attenuate the development and expression of morphine-
induced behavioural sensitization (a process considered to be of importance in the 
development of drug addiction)239;240. 
The lack of consistent data on the influence of acute or chronic administration of 
different antidepressants on CPP-inducing stimuli might be related to the fact that even 
in those cases where antidepressants had positive or negative motivational effects, 
these effects were only moderate at best. The ability of the CPP paradigm to 
demonstrate such moderate effects may depend on procedural variables such as the 
use of an unbiased vs. a biased design, the number of conditioning sessions, or the 
strain of mice or rats used. The same is likely to apply to the interaction between 
antidepressants and drugs of abuse. The influence of the former on the effects of the 
latter is only modulatory at best, and the degree of this modulation may depend, apart 
from the aforementioned factors, on the type of drug of abuse, its dose, and its potency 
or efficacy. We are currently investigating the latter hypothesis by testing whether 
pretreatment with antidepressants differentially affects CPP induced by opioids with 
different levels of potency/efficacy. 
 In our previous IVSA study we found that desipramine, unlike venlafaxine, non-
specifically suppressed operant responding (i.e., it reduced responding for heroin as 
well as responding for food) (Magalas et al., 2005 and unpublished data). In the present 
study, venlafaxine did not affect the locomotor response to heroin during the 
conditioning sessions, while desipramine significantly reduced locomotion when 
combined with heroin. This finding is consistent with the observation that the 
attenuating effect of venlafaxine on heroin IVSA was not due to a general behavioural 
suppression, whereas the reduction of heroin IVSA by desipramine was possibly 
confounded by such non-specific effects (see Introduction). 
 In conclusion, the present data do not support the hypothesis that the effect of 
antidepressants on heroin IVSA is due to an attenuation of the rewarding effect of 
heroin. Although the behavioural mechanism underlying the effect of antidepressants 
on heroin IVSA is still unclear, it remains to be tested whether a possible attenuating 
effect of such compounds on the rewarding effect of an opioid depends on the intrinsic 
potency/efficacy of the opioid. 
 
Acknowledgements: The technical assistance of W. Bruckmann is greatly 
acknowledged. 
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7 Results – summary 
Daily treatment with venlafaxine (10 mg/kg i.p.) before the operant session 
attenuated the acquisition of responding for heroin, but not for food. However, when 
tested during the maintenance phase in rats showing stable responding, acute 
treatment with venlafaxine only marginally affected operant responding for heroin under 
the fixed ratio:10 schedule of reinforcement, and neither acute nor subchronic (once 
daily during 4 weeks) venlafaxine treatment affected responding under the progressive 
ratio. Thus, daily treatment with an antidepressant attenuates the acquisition of heroin 
SA in a behaviourally specific manner, while having only marginal effects on the 
maintenance of heroin SA. 
The effect of desipramine on operant responding for heroin and food was 
assessed during the maintenance of SA behaviour. Acute treatment with desipramine 
(10 mg/kg i.p.) before the operant session attenuated the maintenance of responding 
for heroin under the fixed ratio, however, food-intake was also affected questioning the 
specificity of the effect. Furthermore neither acute nor subchronic (once daily during 4 
weeks) pretreatment with desipramine (10 mg/kg i.p.) affected the maintenance of 
responding for heroin under the progressive ratio schedule. Thus, acute treatment with 
desipramine attenuated the maintenance of heroin SA under the fixed ratio but not 
under the progressive ratio schedule.  
When tested alone, heroin (0.05 – 3.16 mg/kg i.p.) produced a dose-dependent 
CPP. Neither venlafaxine nor desipramine (1 – 21.5 mg/kg i.p.) produced a place 
conditioning effect at the doses tested. Neither acute nor repeated administration of 
saline, venlafaxine (10 mg/kg i.p.), or desipramine (10 mg/kg i.p.), modified the 
acquisition or expression of heroin (0.5 mg/kg) -induced CPP. Thus, the CPP study did 
not support the hypothesis that the previously observed attenuation of acquisition of 
heroin IVSA by venlafaxine is due to an antidepressant-induced attenuation of the 
rewarding effect of heroin. While venlafaxine did not affect the locomotor response to 
heroin, desipramine significantly decreased locomotor activity in combination with 
heroin. This confirms that previous observed reduction in the response rate produced 
by desipramine was due to general behavioural suppression. 
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 8 Conclusions 
Venlafaxine was found to attenuate the acquisition of IVSA of heroin in a 
behaviourally specific manner; while having little effect on responding for heroin in the 
maintenance phase. Decrease in heroin but not in food intake indicated that 
venlafaxine to some extent can “stabilise” circuits engaged in reward and motivation so 
that drug taking behaviour is not compulsive. Because venlafaxine is effective in 
treatment of obsessive-compulsive disorder241, it can in principle, display some effects 
on craving, which is a compulsive drug seeking and taking. Thus, venlafaxine appeared 
to attenuate the rewarding and reinforcing effects of heroin moderately. Acquisition 
refers to initial phase of development of addiction and maintenance refers to already 
established drug seeking and taking behaviour. Thus, it may be supposed that 
antidepressants can delay the development of addiction, however they have no effect 
on already existing addiction. It is noteworthy that in the present study no indication for 
an enhanced intake of heroin was found. Therefore, it can be postulated that adding an 
antidepressant drug, such as venlafaxine, to an opioid for the treatment of pain would 
not be expected to enhance the abuse liability of the opioid (if anything, the 
combination might reduce abuse liability). Furthermore, venlafaxine showed no effect 
on the acquisition or the expression of CPP produced by heroin. Heroin is a strong 
opioid with very high abuse liability. If venlafaxine exerts only a moderate modulating 
effect on the reinforcing/rewarding effect of opioids, the effects of heroin might be too 
potent to obtain clear and consistent effects of venlafaxine across different 
experimental conditions.  
Testing under the fixed ratio:10 in the maintenance phase, desipramine reduced 
intake of heroin. However, desipramine could affect neither responding under the 
progressive ratio schedule nor the CPP induced by heroin. Moreover desipramine 
inhibited the intake of food under the fixed ratio:10 schedule and significantly reduced 
the locomotor response to heroin in the CPP paradigm. Thus, behavioural inhibition 
contributed to attenuating effect of desipramine on heroin IVSA. Thus, from the IVSA 
data, it is not clear if desipramine also might moderately attenuate rewarding properties 
of heroin. However CPP data suggest that desipramine has no effect on them. Taking 
together, the present data indicate moderate effect of venlafaxine on abuse liability of 
heroin, however, the effect of desipramine is not clear. It remains to be tested whether 
its possible attenuating effect on opioid reinforcing properties depends, for example, on 
the intrinsic potency/efficacy of the opioids. 
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